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Summary 
Ageing is a complex physiological process shaped by nutrition, metabolism and 
hormones, with insulin, responsible for glucose absorption from the blood, being an 
important pro-ageing factor. The metabolic decline observed in ageing is 
characterized by changes in insulin action and body fat distribution, predisposing to 
diseases (atherosclerosis, coronary vascular disease [CVD], hyperlipedemia, obesity, 
insulin resistance and type 2 diabetes mellitus [T2DM]). 
Liver X receptors (LXRs) are nuclear receptors (NRs) that are important in regulating 
cholesterol, lipid and glucose metabolism. Despite the wealth of data supporting the 
role of LXRs in energy metabolism, the information is scarce regarding how they 
integrate multiple inputs in whole organisms across life span.  
The present study was conducted both to investigate how LXRα affects the regulation 
of energy metabolism in a physiological setting and to study sexual dimorphism in 
ageing mice. As such, wild type (WT) and LXRα-/- C57BL/6 mice, both females and 
males, were included. They had free access to food and water throughout the 
experiment and were sacrificed at either 1, 3, 6 or 9 months of age. The relative 
mRNA expression levels of hepatic genes were revealed using qRT-PCR, and several 
components in serum were measured. Our data demonstrate that, in the presence or 
absence of LXRα, several hepatic genes are regulated in an age dependent and/or sex 
dependent fashion. From the results of this thesis, we suggest that several hepatic 
LXRα target genes are regulated during the ageing process, such as the de novo 
lipogenic genes (fatty acid synthase [FAS] and stearoyl-CoA dehydrogenase-1 [SCD-
1]). Their mRNA expression levels at 1 month are dependent upon LXRα. A gradual 
increase in the expression of these genes, occur in LXRα-/- animals aged 1-9 months, 
indicating that other mechanisms/proteins come into play to compensate for the loss 
of LXRα. Furthermore, this is also the first report assessing the link between LXRα 
and circadian gene regulation. Our data show that LXRα is important in regulating 
the basal mRNA expression of the circadian gene, BMAL1, in 1 month old animals. 
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It is therefore tempting to speculate that LXRα is involved in circadian signaling 
pathways. In addition, this study also reveals many differences between female and 
male mice, both in plasma glucose concentration, serum levels (i.e. insulin, 
triacylglycerol (TAG), cholesterol) and relative mRNA levels (i.e. ATP-binding 
cassette [ABC] cholesterol transporters ABCG5/G8, cholesterol 7 α-hydroxylase 
[CYP7A1], Fructose-1,6-bisphosphatase 1 [FBP-1], glucose transporter [GLUT] 2). 
In order to further evaluate the potential role of LXRα in the ageing process through 
glucose and lipid metabolic control, the crosstalk with other tissues/organs, NRs, 
hormones and cofactors must be addressed, as no single pathway is believed to 
function in an isolated manner. Furthermore, it remains to be elucidated if similar 
differences are present in humans.  
 12 
1. Introduction 
1.1 Ageing and disease: Glucose and lipid metabolism 
Although the term “ageing” is generally understood in broad terms, the ageing 
process is extremely complex and multifaceted. Ageing include many processes, 
interactive and interdependent, that determine lifespan and healthspan. Lifestyle and 
other environmental factors can profoundly influence the ageing process and its 
impact on the quality of life. The complexity of molecular and physiological changes 
in the ageing process is not fully elucidated. As such, no single definition of ageing is 
universally accepted. Nevertheless, from a biological perspective, ageing can defined 
as the progressive loss of physiological functions that increase the probability of 
death (1). Other than heredity, ageing is shaped by nutrition, metabolism and 
hormones with insulin, the hormone responsible of glucose absorption from the 
blood, as an important pro-ageing factor (2;3). Several changes normally occur with 
increased life span, including a progressive decrease in most, if not all physiological 
functions, atrophy of most organs, an increased vulnerability to infections, trauma 
and various immune abnormalities (i.e. autoimmune disorders, lymphoproliferative 
disorders, amyloidosis) and an increased susceptibility to malignancy (2). The loss of 
physiological function occurs both within individual cells and within the organism as 
a whole. In addition, the ageing process is characterized by a metabolic decline 
leading to altered distribution of body fat, changes in glucose and lipid metabolism 
and changes in insulin signaling (4-6). Also, insulin sensitivity is normally decreased 
during ageing (7-12), and insulin resistance is an important risk factor (13;14) for a 
variety of illnesses that affect morbidity and mortality among the elderly (15;16). 
However, not all studies show a positive correlation between insulin resistance and 
ageing (17;18), and some studies show that insulin sensitivity is unchanged in healthy 
subjects with increased age (19;20). Together, the abovementioned metabolic factors 
affect life span both in invertebrates and in mammals. It is known that dysregulated 
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glucose and lipid metabolism increase the risk for several age-related diseases (i.e. 
insulin resistance and T2DM (21), atherosclerosis, hyperlipidemia and obesity, all of 
which can precipitate to cardiovascular (22) and neuropsychiatric diseases (23)). NRs 
function throughout development and ageing as molecular integrators of 
physiological regulations, such as growth, reproduction and metabolism. Multiple 
NRs, including the LXRs, are involved in the control of glucose and lipid metabolism 
(24;25). This makes them potential targets for treatment and prevention of age-
associated diseases. Despite the critical role of LXRs in glucose and lipid 
metabolism, the current knowledge regarding how they integrate multiple inputs in 
whole organisms across life span is fragmental. 
1.1.1 Metabolism 
Metabolism is the sum of all physical and chemical processes by which components 
of living organisms are produced and maintained (anabolism), and also the 
transformation by which energy is made available for the uses of an organism 
(catabolism) (26). The energy in nutrients can be converted into energy in the 
organism and used for activity, growth, development and reproduction. Metabolic 
pathways involved in processing carbohydrates, lipids and amino acids are 
quantitatively the most important in energy metabolism. Each pathway is composed 
of multienzyme sequences, and each enzyme may exhibit important catalytic or 
regulatory features. In living organisms and cells these metabolic pathways intersect, 
forming an integrated and purposeful network of chemical reactions. The complex 
control of each pathway by hormones, transcription factors (TFs) and other 
components is not yet fully understood. 
1.1.2 Insulin, glucose and lipid metabolism 
During evolution mammals have evolved to maintain energy balance under various 
nutritional conditions. However, this ability is ill-suited to the lifestyles of modern 
society, as evidenced by the fact that obesity has reached epidemic proportions in 
 14 
many industrialized countries. The essence in energy homeostasis is the ability to 
sense the amounts of circulating nutrients and maintain tightly controlled nutrient 
levels by adjusting metabolic pathways. Many hormones and nutrients impinge on 
metabolic networks leading to homeostasis. Glucose and lipid metabolism are 
intimately linked through crosstalk with insulin as one of the most important 
hormonal factors (27). Insulin is a peptide hormone produced and secreted from 
pancreatic β-cells in response elevated glucose concentrations in plasma. Increased 
secretion of insulin occurs after consumption of glucose or a carbohydrate rich meal, 
leading to elevated plasma levels within minutes (28). Although glucose is the main 
stimulus to insulin secretion, amino acids and ketone bodies are also stimulators, 
albeit to differing extents. The main role of insulin is to keep glucose levels within a 
narrow range regardless of fluctuations in dietary glucose and lipid ingestion (29). 
Insulin has its most prominent effects in liver, muscle and adipose tissue (Figure 1.1). 
Glucose derived from diet or endogenous sources stimulates insulin secretion, which 
in turn, promotes glucose uptake by skeletal muscle and adipose tissue, inhibits fat 
lipolysis and opposes hepatic glycogenolysis and gluconeogenesis. Being one of the 
most important anabolic hormones, insulin promotes storage of carbohydrates, lipids 
and proteins, while inhibiting their degradation and release into the blood.  
Diet and endogenous synthetic pathways provide the body with its requirement for 
lipids. The synthesis of fatty acids (FAs) and cholesterol can occur in any cell, and 
increases the multiple lipid compounds. This is especially important in liver and 
adipose tissue; organs specialized in lipid transport and storage. FA synthesis 
increases in response to elevated levels of plasma glucose, as seen in obesity and 
T2DM (30). Free FAs liberated from adipose tissue contribute to insulin resistance in 
the liver and skeletal muscle (27). The identification of key regulators in controlling 
expression of genes involved in glucose and lipid metabolism have revolutionized the 
understanding of the intimate link between these metabolic pathways. It is evident 
from numerous studies that the balance of levels of receptors, cofactors and ligand 
availability is fundamental in controlling energy homeostasis, as discussed later. 
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Figure 1.1. Tissue-tissue crosstalk between glucose and lipid metabolism. 
Glucose stimulates insulin secretion. Fat derived signals, including adiponectin, 
resistin and TNF-α, modulate insulin sensitivity and FA metabolism in muscle and 
liver. See text for more details. Adapted from (27). 
1.2 Nuclear Receptors 
In eukaryotes, transcription is performed by RNA polymerase- I, II or III (31). They 
exhibit similar structure and function, but transcribe different types of genes. RNA 
polymerase I and III transcribe genes encoding transfer RNA, ribosomal RNA and 
various small RNAs, whereas RNA polymerase II is responsible for transcription 
encoding proteins, the messenger RNAs (mRNAs). Most eukaryotic genes have 
coding sequences (exons) interrupted by noncoding sequences (introns). TFs regulate 
gene expression by binding to sequence specific sites (transcriptional regulatory 
domains) in the promoter of their target genes (32). These elements are often referred 
to as response elements (RE), cis elements or enhancer elements (Figure 1.2).  
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Figure 1.2. A model of transcriptional control regulating gene expression. A 
complex arrangement of multiple clustered enhancer modules interspersed with 
silencer and insulator elements which can be located 10-50 kb either upstream or 
downstream of a composite core promoter containing TATA box (TATA), Initiator 
sequences (INR) and downstream promoter elements (DPE). Adapted from (32). 
The expression of genes may depend on RE upstream or downstream the 
transcription start site (TSS), but they are usually located immediately 5’ of the TSS. 
The complex regulation of genes involves several different sets of REs.  
Different combinations of TFs expressed in various cell types ensure a strict control 
of gene transcription, ultimately leading to satisfy the needs of each cell (31).  
NRs are primarily understood as intracellular TFs that directly regulate gene 
expression, generally in response to lipophilic molecules (33). They are part of a NR 
superfamily, describing an evolutionary conserved group of TFs, all of which share 
common structural features (24), despite variation in ligand sensitivity (Fig 1.3.A) 
(34).  
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Figure 1.3. The nuclear receptor superfamily. (A) Schematic structure of NRs. (B) 
Classification of NRs according to physiological proporties and source and type of 
ligand. Adapted from (34).  
Even before the first genes encoding NRs were cloned, it was known that they are 
modular proteins with three major domains (Figure 1.3.A) (35). The N-terminal 
domain contains a ligand-independent transcription function (AF-1). This 
transactivation domain is recognized by cofactors and/or other transcription factors. 
In the core, the highly conserved DNA binding domain (DBD) is located. It contains 
two zinc finger motifs responsible for targeting the receptor to its specific DNA 
responsive element (RE), located in the promoter of target genes (33;36). A large 
ligand binding domain (LBD), is located in the C-terminal half of the receptor. This 
domain directs specificity to a biological response by recognizing and binding 
specific hormonal and nonhormonal ligands, dimerisation, interaction with heat shock 
proteins, nuclear localization and transactivation. The LBDs of all NRs share a 
common three-dimensional structure (37). A variable length hinge region (D domain) 
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between the DBD and LBD permits a flexible three-dimensional structure, allowing 
simultaneous receptor dimerisation and DNA binding. Two nuclear localization 
signal sequences are found in the hinge and C-terminal region. Some NRs have an 
additional domain at the C-terminal (F-region). However, the function of this domain 
is not fully understood. When a ligand is associated to its receptor, the conformation 
is changed. This facilitates dissociation of corepressors, recruition of coactivators and 
binding of the complex to the DNA in the promoter region of specific target genes 
(34). In the absence of a ligand, the LBD of many, but not all NRs (i.e. not steroid 
receptors) is bound to a set of transcriptional corepressors, which recruit 
transcriptional complexes that contain specific histone deacetylases (HDACs) (38). 
These deacetylases create a condensed chromatin structure over the gene promoter, 
leading to gene repression (Figure 1.4). 
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Figure 1.4. Nuclear receptors in action. After diffusion through the cell membrane, 
the ligand can bind to its cognate receptor where it can interact with kinases directly 
and thereby exert “non-genomic effects” (a). The ratio between cytoplasmatic and 
nuclear location can vary between different nuclear receptors and is influenced by the 
nature of the ligand. Ligand binding modulates the interaction of the receptor with 
numerical factors. In the absence of ligand, several NRs are believed to be bound to 
regulatory regions of the target genes as a corepressor or histone deacetylase (HDAC) 
complex (b). Histone deacetylation is responsible for the chromatin condensation that 
accounts for the gene-silencing effect of apo receptors. Ligand binding releases the 
HDAC complex (c) and leads to the recruitment of histone acylatransferases (HAT) 
and chromatin remodelling (CRM) complexes (d). The temporal order and 
requirement of these complexes can occur in a receptor-, target-gene- and cell-
specific manner. In the final step (e), the polymerase II holoenzyme, which comprises  
the pol II enzyme, TAF (TATA binding protein-associated factor) and mediator 
complexes, is recruited and increase the frequency of transcription initiation. Adapted 
from (38). 
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There are NRs in all cells of our body. To this date, the humane genome is reported to 
contain 48 members of the NR superfamily (39). Depending on their physiological 
function and type of ligand, NRs can be subdivided into endocrine receptors, adopted 
orphan receptors and orphan receptors (Fig 1.3.B). The classic endocrine receptors 
mediate actions of steroid hormones, thyroid hormones and the fat soluble vitamins A 
and D (40). They bind ligands with high affinity. This subgroup is divided in two, the 
steroid nuclear hormone receptors (Fig 1.3.B; blue box) and receptors for thyroid 
hormone (TR), retinoic acid (RAR), vitamin D (VDR) and ecdysone (EcR) (Fig 
1.3.B; purple box). They bind to the DNA as dimers; steroid receptors as 
homodimers, the rest heterodimerise with RXR. The steroid receptors include 
receptors for estrogen (ER), progesterone (PR), androgen (AR), glucocorticoid (GR) 
and mineralcorticoid (MR). They bind ligands synthesized from endogenous 
endocrine sources, to control reproduction, carbohydrate metabolism and electrolyte 
homeostasis.  
The orphan NRs (Fig 1.3.B; black box) have no identified ligands. It is not known 
whether all orphan receptors have the ability to bind natural or synthetic ligands or 
whether they are true orphan receptors that do not contain a ligand-binding pocket 
and might be regulated by alternative mechanisms. Orphan receptors become adopted 
when they are shown to bind a physiological ligand.  
Adopted orphan NRs (Fig 1.3.B; red box) heterodimerise with RXR. They bind 
dietary lipids with low affinity and act as lipid sensors in the body by maintaining 
lipid homeostasis through transcriptional control of genes involved in lipid 
metabolism, storage, transport and elimination. NRs compromised in this group are 
receptors for FAs (PPARs), oxysterols (LXR), bile acids (FXR) and xenobiotics 
(Pregnane X Receptor/ Steroid Xenobiotic Receptor [PXR/SXR] and Constitutive 
Androstane Receptor [CAR]). It should be emphasized that the response of a given 
NR to a particular ligand in a specific tissue is dictated by a number of other proteins 
interacting with this NR following ligand-induced allosteric changes that generate, 
expose or remove interaction surfaces. The proteins that interact with the specific NR 
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may range from other NRs and transactivators to transcriptional cofactors. A number 
of transcriptional coactivators play important roles in the integration of metabolic 
processes, including peroxisomal proliferator coactivator (PGC)-1α, PGC-1β, steroid 
receptor coactivator 1 and transcriptional intermediary factor 2 (41;42). In addition, 
corepressors can regulate networks of metabolic genes. For example, receptor-
interacting protein 140 (RIP140) promotes lipid storage in adipose tissue by 
inhibiting the expression of genes involved in mitochondrial biogenesis, oxidative 
phosphorylation, and FA oxidation (43-45). RIP140 interacts with several NRs, 
including peroxisome proliferator activated receptors (PPARs), estrogen-receptor 
related receptors (ERRs) and LXR that regulate metabolic pathways (46;47). RIP140 
is important in regulating the function of LXR in vivo in two distinct ways; the 
induction of lipogenesis and the repression of gluconeogenic genes (48). 
Most NRs bind to their specific RE as homo- or heterodimers with other members of 
the nuclear receptor family. The RE exists as half-sites (six nucleotide sequence) 
separated by variable length of nucleotides between direct or inverted half-site 
repeats (Fig 1.5). For instance, the thyroid hormone receptors (T3Rs) preferentially 
bind to two AGGTCA half sites orientated as direct repeats with a four-base spacer 
(DR4); retinoic acid receptors (RARs) bind to the same AGGTCA half sites, but 
orientated as a DR5; estrogen receptors bind to AGGTCA half sites orientated as an 
inverted repeat with a three-base spacer (INV3); and androgen receptors (ARs) 
recognize an INV3 orientation containing AGAACA half sites (33). 
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Figure 1.5. Nuclear receptor binding to DNA. A nuclear receptor dimer bound to 
the RE upstream of a target gene. Each receptor is represented as two domains: DNA 
binding and hormone binding. The RE shown here is composed of two AGGTCA 
half sites in a direct repeat separated by a spacer; different half-site sequences, and 
orientations select for binding of different nuclear receptors. Adapted from (33). 
1.2.1 Liver X Receptors 
Cholesterol and sterol homeostasis is an important regulatory pathway closely 
controlled by NR function. Pathologic levels of cholesterol in the blood are 
detrimental as they may lead to excessive accumulation in vessel walls, a condition 
which might precipitate to atherosclerosis and CVD. Liver X Receptors (LXRs) are 
major cholesterol sensors in the body and play an essential role in regulating 
cholesterol and FA homeostasis (49-51). They are crucial in regulating genes in 
different steps involved in reverse cholesterol transport (52;53), the process of 
removing cholesterol from the vessel wall and transporting it to the liver, and genes 
involved in bile acid biosynthesis and excretion (54;55).  
LXRα (NR1H3 (Nuclear Receptor Nomenclature Committee, 1999) also described as 
RLD-1) was first isolated from rat liver and later human liver, hence the name Liver 
X Receptor (56;57). Later LXRβ (NR1H2, also described as OR-1/UR/NER/RIP15) 
was identified (58-61). Both isoforms are highly related and share 78% amino acid 
sequence in both the DBD and LBD. LXRα is predominantly expressed in 
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macrophages and in metabolic tissues, such as the liver, skeletal muscle, adipose 
tissue, small intestine and kidney, but a lower expression level is also seen in the 
spleen, adrenal and pituitary glands (56;57;62). LXRβ is ubiquitous (58-61). The 
LXR/RXR heterodimer binds to a DR4 (AGGTCA   nnnn   AGGTCA) LXR 
response element (LXRE) in the promoter of target genes (57;61). The LXRs are 
activated by endogenous levels of oxysterols, oxidised cholesterol derivatives, such 
as 22(R)-hydroxycholesterol, 27- hydroxycholesterol and 24(S),25-epoxycholesterol 
(51;63;64). Desmosterol, the direct precursor of cholesterol in the biosynthesis, has 
also been shown to activate LXR in vitro (65) and in vivo (66). Recently, it has been 
suggested that physiological concentrations of glucose expected in the liver bind and 
stimulate LXR with efficacy similar to that of oxysterols (67), suggesting that glucose 
is an endogenous LXR ligand. However, further evidence is needed to validate 
glucose’s effects on LXR, leaving glucose as an uncertain ligand to this date. Acetyl-
Podocarpic Dimer (APD) (68), T0901317 (49) and GW3965 (69) have all been 
described as synthetic compounds with ability to activate LXRs. The two latter do not 
share the same ligand specificity for LXRs. It has been shown that T0901317 also 
functions as a high-affinity ligand for PXR. Induced expression of PXR target genes, 
such as the scavenger receptor CD36, is also seen upon T0901317 stimulation, a 
property not shared by the more specific LXR ligand GW3965 (70). Recently, the 
synthetic ligand, 15-ketosterol, has also shown to bind LXRs with efficacy similar to 
that of oxysterols (71). Furthermore, polyunsaturated FAs (PUFAs) are found to be 
competitive inhibitors of LXR ligands (i.e. oxysterols), antagonizing LXR activity by 
inhibiting LXR/RXR binding to the LXRE (72;73), while FAs are positive regulators 
of LXRα gene expression in cultured hepatocytes (74). LXR/RXR is a so-called 
permissive heterodimer, in that it can be activated by ligands for either LXR or RXR. 
A synergistic activation is obtained if ligands for both NRs are present.  
LXRs regulate key aspects of cholesterol, FA and carbohydrate metabolism (30;75-
77). The generation of mice devoid of LXRα (LXRα-/-) has revealed key roles of 
LXRs in lipid homeostasis. LXRs regulate expression of multiple genes involved in 
efflux, transport and excretion of cholesterol and the FA synthesis pathway, as well 
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as lipoprotein metabolism (78-80). The first gene described as a direct LXRα target, 
CYP7A1, is regulated in mice, but not in humans (81). CYP7A1 is the rate limiting 
enzyme responsible for conversion of cholesterol to bile acids in liver. In the liver, 
LXR is also involved in transcriptional control of ABCG5 and ABCG8 (82;83), ABC 
transporters implicated in the bilary cholesterol excretion. Induction of intestinal 
ABCA1, ABCG5/G8 expression upon LXR activation is thought to limit the 
efficiency of cholesterol absorption and hence to accelerate fecal cholesterol disposal 
(53). LXRα-/- mice exhibit a vast hepatic cholesterol accumulation due to impaired 
cholesterol and bile acid metabolism, ultimately causing defective liver function. 
Excess extra-hepatic cholesterol must be transported to the liver and excreted as 
cholesterol or bile acids into the bile, and ultimately into the gut. Furthermore, 
macrophages play an essential role in this reverse cholesterol transport as excess 
cholesterol may convert these cells into foam cells and thereby promote 
atherosclerosis. In macrophages, the ABC transporters, ABCA1/G1, are regulated by 
LXRs (81;84). These transporters are involved in transport of cholesterol and 
phospholipids from cells to extracellular cholesterol acceptors, notably the lipid-poor 
apolipoproteins apoA1 and apoE. Reverse cholesterol transport is correlated with 
levels of the lipoprotein HDL. ApoE is a component of HDL that is regulated by 
LXR in macrophages and adipocytes, further underlying the role of LXR in 
cholesterol metabolism (78;79). Taken together, these and other studies provide 
compelling evidence for LXR as an important cholesterol sensor in the body 
(63;80;81;85) and that it might enhance reverse cholesterol transport in a tissue-
specific manner. Furthermore, cholesterol ester transfer protein (CETP) (86) and 
phospholipid transfer protein (PLTP) (87) compromise lipid transfer proteins 
regulated by LXRs. CETP transports cholesteryl esters from HDL to the 
apolipoprotein B-100-containing lipoproteins very low density lipoprotein (VLDL), 
intermediate density lipoprotein (IDL) and low density lipoprotein (LDL) (88). This 
leads to cholesteryl ester clearance when IDL and LDL particles are taken up by the 
liver. PLTP, in turn, is involved in the generation of efficient acceptors of cellular 
cholesterol (preβ-HDL) by transferring excess lipoprotein surface phospholipids 
(surface remnants) to the lipid-poor apoA-1. The remnants are generated when 
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lipoprotein lipase (LPL) hydrolizes TAG-rich lipoproteins, such as VLDL (89). 
LXRs also control the synthesis of LPL (90). This enzyme is located on the luminal 
surface of vascular endothelial cells. By hydrolyzing TAGs, it liberates FAs into 
adipose tissue for storage and into skeletal muscle for energy expenditure. Thus, 
LXRs are involved in FA metabolism by both promoting their synthesis and their 
clearance by uptake in peripheral tissues. As LXRs stimulate synthesis of FAs in the 
liver, the increased quantity of FAs in hepatocytes become available for synthesis of 
TAGs, which are subsequently secreted into the circulation as VLDLs. LXRα-/- mice 
exhibit disturbances in capacity to regulate genes involved in FA and TAG secretion 
due to deficiency of a number of lipogenic genes, such as the sterol regulatory 
element-binding protein (SREBP)-1c, FAS, acetyl-CoA carboxylase-α (ACC-α) and 
SCD-1 (30). FAS, ACC-α and SCD-1 are directly regulated by SREBP-1c, 
supporting the role of LXR not only in sterol metabolism, but also in FA metabolism 
in general. LXR can also directly stimulate hepatic transcription of SREBP-1c 
(91;92), FAS (93) and ACC-α (94) through LXREs in their promoters. Basal LXR 
activity is essential for hepatic SREBP-1c expression, further supporting the role of 
LXR in hepatic lipogenesis (95). Activation of both LXR and SREBP-1c seem to 
induce the lipogenic pathway to bigger extent compared to separate activation (93). 
Our group has previously investigated the link between LXRs and insulin, as the 
effect of LXR activation on hepatic gene expression is similar to the effects of insulin 
in this tissue. Tobin et al. reported that LXRα expression in liver is induced by 
insulin (96). In addition, it seems that LXRs crosstalk with insulin to regulate hepatic 
lipogenesis, since insulin-mediated induction of key enzymes in hepatic FA synthesis 
were significantly suppressed in insulin-injected LXRα-/-β-/- mice (96). 
LXRs are also regulators of glucose metabolism. It has been previously shown that 
ligand activated LXRs inhibit expression of phophoenolpyruvate carboxykinase 
(PEPCK), the rate-limiting step in gluconeogenesis (97;98). This effect was 
paralleled by downregulation of 11β-hydroxysteroid dehydrogenase 1 (11β-HSD-1), 
which converts inactive corticosteroids into active corticosteroids (i.e. cortisol) (98). 
The downregulation of hepatic gluconeogenic genes, such as PEPCK and glucose-
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phosphatase (G6P), in LXR agonist-treated mice, has also been shown by others 
(75;99). This inhibition was accompanied by induced glucokinase (GCK) expression, 
an enzyme which promotes hepatic glucose utilization (75). In addition, our group 
has shown that the insulin-dependent glucose transporter, GLUT4, is directly 
transactivated by LXR in adipose tissue (100). Along this line, activation of LXRs 
improves glucose tolerance in diabetic rodents through coordinate regulation of 
glucose metabolism in liver and adipose tissue (99). Another linkage between glucose 
and lipid metabolism mediated through LXR, was described by others when the 
expression of the carbohydrate responsive element binding protein (ChREBP), which 
promotes transcription of hepatic lipogenic enxzymes, was shown to be regulated by 
LXR activation (101;102). This glucose-sensitive transcription factor is involved in 
converting excess carbohydrates to lipids (103;104). 
Together, these data raise the intriguing issue of LXR as an important co-regulator of 
glucose and lipid metabolism, providing a molecular basis for the close relationship 
between these metabolic pathways (Figure 1.6.). 
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Figure 1.6. Convergence of glucose and lipid-sensing pathways on the nuclear 
receptor LXR. Mitro et al. (67) suggests that glucose is an endogenous ligand with 
the same efficacy to that of oxysterols, the known high-affinity ligand for LXR. The 
strength of LXR signaling can fluctuate widely, depending on nutritional states. LXR 
heterodimerise with RXRα in vivo and activate genes in the 
gluconeogenic/glycolytic, FA synthesis and cholesterol pathways in order to control 
nutrient and energy homeostasis. “?” denotes hypothetical or speculative elements. 
Modified from (105). 
Synthetic LXR agonists inhibit atherosclerosis pathology in mice, an effect likely to 
result from modulation of both metabolic and inflammatory gene expression (106). 
Interestingly, LXR ligands could also mediate beneficial metabolic effects in insulin 
resistance syndromes, such as T2DM, by interfering with peripheral glucocorticoid 
activation. The antiatherogenic and antidiabetic effects observed in physiologic 
studies, is paralleled by a shift in metabolism to energy storage; a shift that includes 
lowering of glycemia and an increase in lipid accumulation (75). Furthermore,since 
the liver contains predominantly LXRα, LXRβ-specific agonists or tissue-specific 
LXR modulators may be effective in macrophage reverse cholesterol transport with 
less impact on LXRα mediated induction of hepatic lipogenesis. The design of LXR 
selective ligands is challenging due to the high homology in the LBDs in both LXR 
isoforms. Recently, Hu et al. were able to show that carboxylic acid based quinolines 
have some selectivity for LXRβ over LXRα in binding assays (107), but the search 
for selective LXR ligands is still under investigation.  
1.3 The liver 
The adult human liver weighs 1-1.5 kg, and lies under the diaphragm. It is supplied 
with blood from the hepatic artery (~20%) and the hepatic portal vein. This vein 
carries blood which has passed through the complex network of blood vessels 
surrounding the intestinal tract. Thus, the water-soluble substrates arising from the 
diet (i.e. monosaccharides and amino acids) are transported to the liver before 
entering the general circulation, giving the liver a crucial role in metabolism. A small 
group of veins, the pancreatic veins, join the portal vein before it enters the liver. 
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These veins carry blood containing insulin and glucagon from the endocrine part of 
pancreas, allowing these hormones to exert their first effects on the liver, before 
being diluted in the general circulation. Almost half of the secreted insulin reaching 
the liver is removed in its “first passage.” Blood leaves the liver in numerous hepatic 
veins, which enters the inferior vena cava. Hepatic ducts carry bile acids to the gall 
bladder, located immediately under the liver (108). Bile contains bile salts, essential 
to digestion and absorption of fats from the intestine. During digestion, they reach 
duodenum through the common bile duct. Approximately 80% of the liver contains 
hepatocytes, arranged in hexagonal units (lobules). Other cell types include Kuppfer 
cells and endothelial cells. The liver has important roles in carbohydrate metabolism 
(storage and release of glucose), amino acid metabolism and a smaller role in fat 
metabolism (28).  
The liver can take up large amounts of glucose (i.e. following a carbohydrate-rich 
meal) and release it when it is required elsewhere in the body. Liver cells 
predominantly have GLUT2, a glucose transporter, which is not responsive to insulin 
and has a high Km. Within hepatocytes, glucose is phosphorylated by GCK to 
glucose-6-phosphate. This glucose metabolite can enter the glycogenic pathway or be 
metabolised to pyruvate via glycolysis. In both pathways, the regulation is brought 
about by a change in the balance of hormones, including glucagon, catecholamines 
and insulin. In liver, the induction of genes encoding enzymes involved in de novo 
lipogenesis occurs in respons to increased levels of glucose available (Figure 1.7). In 
this way, excess dietary carbohydrates can be converted into TAGs (109). 
Like many other tissues, the liver is able to take up non esterified fatty acids (NEFAs) 
from the plasma. These FAs can either be oxidized (mitochondrial β-oxidation) or 
used in TAG formation. Their fate is mainly controlled by insulin and glucagon. In 
fed state, when insulin is elevated, the liver tends to store FAs as TAG, rather than to 
oxidize them. The TAG formed by esterification of FAs, is stored within hepatocytes, 
appearing to be a local store for hepatic needs. The stored TAG acts as the substrate 
for hepatic secretion of fat into the bloodstream, in the form of VLDL. During 
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starvation or between meals, the ATP-required formation of glucose, the 
gluconeogenic pathway, can be fuelled by the oxidation of FAs. The liver also has a 
special role in cholesterol metabolism. Excess cholesterol is converted into bile acids 
and exported from the cell, while a simultaneously reduction in cholesterol 
biosynthesis and uptake of lipoprotein cholesterol takes place.  
 
Figure 1.7. LXR regulate de novo lipogenesis in liver through target genes, directly 
(ACC, FAS, SCD-1) and indirectly (through SREBP-1c and ChREBP). Glucose is 
metabolized into Acetyl-CoA, which serves as a substrate for lipogenesis. 
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2. Objectives 
The work in this thesis takes part in an EU funded project, CRESCENDO, with the 
overall aim to enhance the understanding of basic mechanisms underlying NR actions 
and their translation into the physiological regulation of development and the ageing 
process. CRESCENDO has 3 major aims: 
• To enhance understanding of NR signaling in the context of regulatory 
networks. 
• To study the roles of NRs in the continuum of development to ageing, with 
emphasis on the complex links between NR signaling, metabolic disease, as 
well as brain development and ageing. 
• To transfer this knowledge into therapeutic leads. 
In this master thesis I want to investigate the link between the ageing process and 
how it affects the glucose and lipid metabolism in vivo. The main goal is to elucidate 
the contribution of LXRα and its interacting ascending and descending signaling 
cascades in regulating glucose and lipid homeostasis in ageing under normal 
physiological conditions. In order to contribute and achieve this goal, we included 
female and male LXRα-/- and WT mice (1, 3, 6 and 9 months old). 
The objectives of this thesis are to: 
• Describe changes in ageing WT and LXRα-/- mice (female and male, 1-9 
months) regarding: 
o Bodyweight, organweight (liver, white adipose tissue (WAT)) 
o  Physiological parameters in serum (glucose, insulin, cholesterol, FAs, 
TAGs)  
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o Hepatic gene expression encoding proteins in glucose, lipid and 
cholesterol metabolism, as well hepatic genes encoding TFs (SREBP-
1, ChREBP) and NRs (ERα). In order to analyze the transcriptional 
cascades in the liver, hepatic total RNA is isolated by Trizol® reagent, 
cDNA is synthesized and qRT-PCR is applied. 
• Describe differences (bodyweight, organweight, serum levels, and hepatic 
gene expression) between male and female mice with increased lifespan (1-9 
months). 
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3. Materials 
Chemicals      Manufacturer 
Chloroform      Sigma 
DEPC       Sigma 
Ethanol      Merck 
Isopropyl alcohol     Arcus 
RNase-away      Molecular Bio Product 
Taqman ® Universal Master Mix   Applied Biosystems 
TRIZOL® Reagent     Invitrogen 
Equipment      Manufacturer  
Falcontubes      Falcon 
MicroAmp Optical 96-well Reaction Plate Applied Biosystems 
Microtubes      Axygen 
PCR-tubes      Sarstedt 
Pipettes      Biohit 
Repeating pipettes     Rainin 
Pipette-tips      Thermo 
Instruments      Manufacturer 
Accu chek Aviva (Glucometer)   Roche 
Acculab Econ (Weight)    Acculab 
AX105 DeltaRange (Weight)   Mettler Toledo 
ABI PRISM® 7900HT SDS   Applied Biosystems 
Biofuge fresco (Centrifuge)   Heraeus instruments 
Titertek Multiskan ® PLUS   Labsystems Oy 
Freezer, -76 oC     Forma Scientific 
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GeneAmp PCR System 9700   Applied Biosystems 
ND-1000 Spectophotometer   NanoDrop 
MilliQ-synthesis     Millipore 
Pipeteboy Comfort     Integra Biosciences 
Kits       Manufacturer    
High Capacity cDNA Archive Kit   Applied Biosystems  
TaqMan Gene Expression Assay   Applied Biosystems 
Low Density Arrays     Applied Biosystems 
Ultrasensitive Mouse Insulin ELISA  Mercodia 
Software and internet resources  Manufacturer 
Adobe Illustraor CS2/CS3    Adobe 
Primerdesign      Applied Biosystems 
Microsoft Office     Microsoft 
NanoDrop Software V.3.2.1.   Nanodrop 
Pubmed      National Library of Medicine 
RQ Manager Software     Applied Biosystems 
Sequence Detection System software  Applied Biosystems 
SPSS 14.0 for Windows    SPSS Inc. 
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4. Methods 
4.1 Animal experiments 
All use of animals have been approved and registered by the Norwegian Animal 
Research authority. Animals used in this experiment were LXRα-/-β+/+ mice, 
generated as previously described (110-112) as well as wild type littermates. All mice 
had a similar mixed genetic background based on 129/Sv and C57BL/6 strains, 
backcrossed in C57BL/6J mice for ten generations. The animals were housed in a 
controlled environment; constant temperature (22°C) and humidity, light from 6 a.m. 
to 6 p.m. They were fed ad libitum on a standard chow diet with the following 
composition in terms of energy: 64 % carbohydrate, 4.5 % lipids and 31.5 % proteins 
(Special Diet Services). Animals had free access to water throughout the experiment. 
They were housed according to age, genotype and sex, four to six animals per cage. 
Upon arrival the mice were acclimatized for at least one week before sacrifice. At the 
time of sacrifice, body weight was measured, correct to ± 0.1 g using an Acculab 
ECON scale. All animals were euthanized by cervical dislocation at the same time of 
the day, three hours after the end of dark cycle (Zeitgeber Time 3, ZT3) at 1, 3, 6 or 9 
months of age. Blood was collected by cardiac puncture, glucose was measured and 
organs (heart, liver, pancreas, white adipose tissue [epididymal and subcutaneous], 
musculus soleus and musculus gastrocnemius) were excised. The weight of liver and 
epididymal adipose tissue was registered, and a small piece was taken to determine 
the lipid profile in the tissues. Organs were snap frozen in liquid nitrogen (-196°C) 
and stored at -76°C until isolation of total RNA. Separation of serum was done by 
centrifuging the blood samples at 7000 rpm, 4°C for 7 min. Serum was transferred to 
new tubes and stored at -76°C until further analyzes.  
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4.2 RNA analysis 
RNA is at risk of degradation by ribonucleases (RNases), which may be introduced 
accidentally into the RNA preparation at any point in the isolation process through 
improper technique. Contamination may come from the lysed cells, working 
solutions or most commonly; bacteria and molds on the hands of the worker or dusty 
laboratory equipment. In the presence of TRIzol® reagent, RNA is protected from 
RNase contamination. Downstream sample handling requires that nondisposable 
glassware or plasticware is RNase-free. RNase activity is difficult to inhibit. It is 
therefore important to prevent its introduction by proper microbiological, aseptic 
technique:  
• All the equipment used is sterile or washed with RNase Away followed by 
rinsing with RNase free water before being used. 
• All water used is Diethyl-pyro-carbonate (DEPC) water (see 4.2.1) or PCR-
grade water. 
• All handling is done using disposable gloves to prevent RNase contamination 
from surface of the skin. Gloves should be changed frequently.  
• Keep tubes closed whenever possible. 
• Equipment and working solutions are kept sterile. 
• Tissues are stored at -76°C, and transported in liquid nitrogen. 
RNase can be deactivated by heat inactivation at 150°C for four hours. Isolated RNA 
is always kept on ice; RNA is stored at -76°C. 
Isolated total RNA can be used for a number of down-stream applications like; 
Northern blot analysis, dot blot hybridization, poly (A)+ selection, in vitro translation, 
RNase protection assay, molecular cloning or cDNA-synthesis. 
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4.2.1 DEPC-water  
DEPC is a strong, but not absolute, inhibitor of RNases. DEPC inactivates RNases by 
covalently modification, and is used to create RNase-free water. This is done by 
adding 125 μl DEPC to 1 l Milli-Q water (0.0125%), wich is deionized water that has 
been purified in a Milli-Q system. The solution is then mixed and incubated at 37°C 
for 12 hours to remove the RNase present. Residual DEPC is autoclaved to eliminate 
the DEPC.  
4.2.2 Isolation of total RNA from liver tissue  
TRIzol® reagent, purchased from Invitrogen (Cat.No 15596-018), was used to isolate 
total RNA from liver tissue. The reagent, a mono-phasic solution of phenol and 
guanidine isothiocyanate, is an improvement to the single-step RNA isolation method 
developed by Chomczynski and Sacchi (113). Guanidinum isothiocyanate and 
chloride denature proteins and inhibit RNases. RNA integrity is maintained while the 
cell structure is ruptured by denaturation of proteins, and nuclear proteins dissociates 
from the nuclear acids. Addition of chloroform, followed by centrifugation, provides 
a phenol-chloroform extraction of RNA and separates the solution into a colorless 
upper aqueous phase, an interphase and a lower red, phenol chloroform phase. RNA 
remains exclusively in the upper aqueous phase. After transferring the aqueous phase, 
RNA can be precipitated with isopropyl alcohol. Total RNA isolated by this method 
is free of protein and DNA contamination.   
Protocol 
Prior to homogenization, keep the tissue in liquid nitrogen. Homogenize 50 to 100 
mg tissue using an Ultra Turrax® T8 (IKA LABORTECHNIK, Staufen Germany) in 
1 ml TRIzol® for 20-30 sec. Incubate homogenized samples for 5 min at 15-30°C to 
allow the complete dissociation of nucleoprotein complexes. Add 0.2 ml chloroform 
per 1 ml of TRIzol® used for homogenization. Cap sample tubes securely. Shake 
tubes vigorously by hand for 15 sec, and incubate at room temperature for 2-3 min. 
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Centrifuge the samples at no more than 12,000 × g for 15 min, 4°C. Transfer the 
RNA, which remains exclusively in the upper aqueous phase following 
centrifugation, to a fresh tube. Precipitate the RNA from the aqueous face by mixing 
with isopropyl alcohol. Use 0.5 ml isopropyl alcohol per 1 ml of TRIzol® reagent 
used for the initial homogenization. Incubate samples at room temperature for 10 min 
and centrifuge at no more than 12,000 × g for 10 min at 4°C. RNA is now visible as a 
gel like pellet on the side and bottom of the tube. Remove the supernatant. Wash with 
75% ethanol, vortex and centrifuge at no more than 7,500 × g for 5 min, 4°C. 
Remove ethanol subsequently and briefly air-dry (not completely) the pellet for 5-10 
min. Re-dissolve the pellet in DEPC-H2O and incubate at 55°C for 10 min. Isolation 
is now completed and RNA should be stored at -76°C. 
Spectrophotometric quantification of nucleic acids 
Concentration, quality and purity of the isolated RNA were determined using a 
NanoDrop® ND-1000 Spectrophotometer that accurately and reproducibly measures 
2 µl nucleic acid samples. It has high absorbance capacity and can measure RNA-
concentrations in the range of 2.0-3000 ng/µl. To do this, the instrument 
automatically detects the absorbance and utilizes the 0.2 mm light pathlength to 
calculate the concentration. Nucleic acids absorb light in the ultraviolet range (200-
400 nm) with an absorption peak at 260 nm. Proteins have an absorption peak at 280 
nm. The ratio OD260/OD280 provides an estimate of purity of the DNA and RNA. A 
ratio of ~ 2.0 is generally accepted as “pure” for RNA. An appreciably lower ratio 
may indicate presence of protein, phenol or other contaminants that absorb strongly at 
or near 280 nm. All samples used had a ratio higher than 1.8. The ratio 
OD260/OD230 is a secondary measure of nucleic acid purity. This value is 
commonly higher (1.8-2.2) than the OD260/OD280 ratio. A very low value may 
indicate the presence of co-purified contaminants. 
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4.2.3 cDNA synthesis 
High Capacity cDNA Archive Kit (P/N: 4322171, Applied Biosystems) was used to 
reverse transcribe total RNA to single-stranded complimentary DNA (cDNA). A 
poly-A sequence at the 3’ end of mRNA is used as a template. The kit uses the 
random primers scheme for initiating cDNA synthesis. Random primers ensure that 
the first strand synthesis occurs efficiently with all species of RNA present, including 
mRNA and rRNA. An essential requirement for the relative quantification of cDNA 
is that the reverse transcription (RT) reaction generates products in a manner directly 
dependent on the amount of input RNA template. The first strand of cDNA can be 
directly used as a template in the polymerase chain reaction (PCR). Conversion of 
total RNA to cDNA is also preferred, as cDNA is considered to be more stable for 
long term archiving and is less susceptible for degradation than RNA. 
Protocol 
Preparing RNA samples and 2×RT master mix 
The reaction volume in the cDNA synthesis was set to 50 µl (25 µl RNA sample and 
25 µl master mix). In this work an input of 3.0 µg total- RNA was used. Before 
sample preparation, allow samples and kit components to thaw on ice. Then prepare 
3.0 µg RNA samples in sterile, RNase free tubes and adjust volume to 25 µl with 
PCR grade water, mix and spin down. The kit contains reagents, which when 
provided, forms a 2×RT master mix. As such, an equal volume of both RNA sample 
and 2×RT master mix should be added. Prepare 2×RT master mix. Pipette 25 µl 
2×RT master mix to each well on a RNase-free 96 well reaction plate. Then pipette 
25 µl RNA sample into wells, pipetting up and down two times to mix. Seal the plate 
with caps, vortex and briefly spin down to eliminate any air bubbles. Place the plate 
on ice until you are ready to load the thermal cycler (GeneAMP 9700). Incubate at 
25ºC for 10 min and 37ºC for two hours. By completion of the reaction the converted 
cDNA is held at 4ºC for short term storage (up to 24 hours). For long time storage 
and archiving, store at either -20ºC or -76ºC. 
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Preparing a 2×RT master mix (20 reactions): 210 µl RNase-free H2O, 100 µl 10× 
Random Primers, 100 µl 10×RT Buffer, 40 µl 25× dNTP mixture and 50 µl 
Multiscribe RT (50 U/ µl). Place the 2×RT master mix on ice until the cDNA reaction 
plate is prepared. 
4.3 Essential RNA - DNA techniques 
4.3.1 Real time polymerase chain reaction  
Real Time PCR 
The PCR is an enzymatic in vitro amplification of a specific DNA segment. DNA 
polymerase amplifies target cDNA synthesized from total RNA, using two sequence-
specific, unlabelled primers and a TaqMan MGB probe (6-FAM dye-labelled) from 
the TaqMan Gene Expression Assay mix. Real Time PCR, also known as qPCR, 
qRT-PCR, RT-qPCR and kinetic PCR, is a quantitative PCR method to determinate 
the copy number of PCR templates, such as DNA or cDNA, in a PCR reaction. 
Reactions are characterized by the point in time during cycling when amplification of 
a target is first detected above a certain threshold, rather than the amount of target 
accumulation after a fixed number of cycles. The higher the copy number of the 
nucleic acid target, the sooner a significant increase in fluorescence is observed. 
There are two types of real time PCR: probe based (TaqMan PCR) and intercalator 
based (SYBR Green PCR). Both methods require a special thermocycler equipped 
with a sensitive camera that detects fluorescence in each well of a 96-well plate at 
frequent intervals during the PCR reaction. Unlike the SYBR Green method, which 
uses a fluorescent dye that only binds to double-stranded DNA, TaqMan PCR uses a 
fluorogentic probe designed to bind only the DNA sequence between the two PCR 
primers. The fluorogentic probe is a single stranded oligonucleotide of 20-26 
nucleotides that contains a reporter dye and a quencher dye, covalently attached to its 
5` and 3` ends, respectively. When the probe is intact, the proximity of the reporter 
dye to the quencher dye, results in suppression of the reporter fluorescence. During 
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PCR, if the target of interest is present, the probe specifically anneals to a 
complimentary sequence between the forward and reverse primer sites. The 5’-3’ 
nucleolytic activity of the DNA polymerase system only cleaves probes hybridized to 
the target (Figure 4.1). Cleavage of the probe separates the reporter dye and the 
quencher dye, displacing probe fragments from the target, while polymerization of 
the strand continues. This separation results in increased fluorescence of the reporter.  
 
Figure 4.1. 5’-3’Nuclease activity of the DNA polymerase system (114).  
The 3’ end of the probe is blocked, preventing extension of the probe during the 
reaction. This process occurs in each cycle and does not interfere with the 
exponential accumulation of the product. Accumulation of PCR products is detected 
directly by monitoring the increase in fluorescence of the reporter. The increase in 
fluorescence is generated only if the target sequence is complimentary to the probe 
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and is amplified during PCR. Therefore any nonspecific amplicons are not detected in 
TaqMan PCR, making it more accurate and reliable than the SYBR Green method. 
Nevertheless, special laboratory practices are required to prevent contamination and 
avoid false positive amplifications (115). The high sensitivity of the PCR assays can 
lead to amplification of a single DNA molecule (116). Follow general PCR practices 
as used when handling RNA. In addition: 
• Maintain separate areas, dedicated equipment and supplies for sample 
preparation, PCR setup, PCR amplification and analysis of PCR products.  
• All surfaces in the PCR area should be routinely decontaminated to prevent 
cross contamination. 
• Never bring amplified PCR products into the PCR setup area.  
• Keep reactions and components capped as much as possible.  
• Open and close all reaction plates and sample tubes carefully. Try not to splash 
or spray PCR samples. 
Besides reagents required for normal PCR, TaqMan PCR requires the 
abovementioned PCR primers with a preferred product size of 50-150 bp, a 
fluorogenic probe and a real-time PCR machine.  
Before PCR starts, a hold at 95ºC is needed to activate the heat stable DNA 
polymerase. The PCR consists of three steps. Firstly the denaturation of the DNA at 
95ºC, secondly annealing at 60ºC, where primers bind to the single stranded DNA, 
and thirdly the elongation of primers, catalysed by DNA polymerase, still at 60ºC, the 
optimal temperature for the heat stable DNA polymerase used. This cycle is repeated 
40-45 times. The amount of target product increases exponentially. If a maximum 
efficiency is obtained, this increase is given by the equation N=N0 × 2n, where N 
equals the number of amplified fragments, N0 equals the initial number of fragments 
and n equals the number of amplification cycles. In the system used in this work 
maximal efficiency can be assumed. 
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Primer design 
A pair of primers is needed by DNA polymerase to amplify the DNA target (i.e. a 
specific genetic sequence) of interest. TaqMan® Gene Expression Assays, ordered 
from Applied Biosysem (www.appliedbiosystems.com), are a comprehensive 
collection of predesigned gene-specific primer and probe sets. TaqMan Gene 
Expression Assays are built on 5’ nuclease chemistry. Each assay consists of two 
unlabeled PCR primers and a FAM dyelabeled TaqMan® MGB (minor groove 
binder) probe. All components are quality control-tested and formulated as a single 
20 × mix. They are designed to run under universal conditions for two-step RT-PCR 
and amplify target cDNA without amplifying genomic DNA (m suffix in assay ID), 
when possible. This is achieved by designing probes that cross exon-exon junctions.  
Primers for specific endogenous controls must be carefully selected. Ideally, an 
endogenous control should be constitutively expressed in all cells, preferably 
expressed in similar levels as the gene(s) of interest and its expression should not 
change in the application. In general, housekeeping genes (i.e. 18S, 36B4, 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) etc.) are the typical choice due 
to their mostly consistent expression levels in all cell types. The selected endogenous 
reference should be determined empirically and based on the system under study. 
Protocol (96 well format) 
The PCR step must be performed on a Real-Time PCR System. Traditional thermal 
cyclers cannot be used, because they cannot detect and record the fluorescent signals 
generated by the cleavage of the TaqMan probes. Perform the PCR in a 96 well 
format. Use 10-100 ng of cDNA per 20 µl reaction volume. Despite the specificity of 
Real-Time PCR using the TaqMan Gene Expression Assay, no template control 
(NTC) and “no amplification control” (without reverse transcriptase) should be run in 
order to check for genomic DNA contamination etc. 
REAGENT PREPARATION: Thaw any frozen cDNA samples and TaqMan Gene 
Expression Assay mix (light sensitive) on ice. When thawed, resuspend by vortexing 
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and then centrifuge the tubes briefly. Prior to use, mix the PCR master mix 
thoroughly by swirling the bottle. Prepare the PCR reaction mix for each sample. Mix 
the solutions by gently pipetting up and down. Cap the tubes and centrifuge them 
briefly. 
PCR REACTION PLATE PREPARATION: Each 20 µl reaction consists of: 10 µl 
TaqMan Universal PCR Master Mix (2×) No AmpErase UNG (P.N: 4324018), 8 µl 
PCR grade H2O and 1µl TaqMan Gene Expression Assays (20×) and 1 µl cDNA 
template. Transfer the correct volume of each reaction mixture to wells of a reaction 
plate that can be used on the 7900HT system. Cover the plate with an optical 
adhesive cover. Centrifuge the plate briefly to spin down content and eliminate any 
air bubbles from the solution that may be present. Visually verify that each reaction is 
positioned at the bottom of its well. Apply a standard compression pad to the sealed 
optical plate. 
RUNNING THE PLATE: Place the reaction plate in the instrument. Run the plate on 
the 7900HT system and select the standard run.  
ANALYZING RESULTS: This involves three procedures: 
1. View the amplification plots for the entire plate to ensure that the 
amplification has been successful.  
2. Set the baseline and threshold values. 
3. Calculate relative gene expression levels. Results were obtained from the 
7900HT system using the Comparative CT method for relative quantification. 
A CT (cycle threshold) value is the fractional cycle number at which the 
fluorescence passes the fixed threshold. The threshold should be set in region 
associated with an exponential growth of the PCR product. To minimize the 
variation in input cDNA, signals generated by the amplifications of the target 
sequence in the cDNA samples should be normalised to signals obtained from 
endogenous controls. For the comparative CT method to be valid, the 
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efficiency of the target amplification (the gene of interest) and the reference 
amplification (the endogenous control) must be approximately equal. The 
formula 2 – ∆ ∆CT was used to calculate results. 
Low Density Array (LDA) 
LDA cards (Figure 4.2) were also used to profile gene expression. These cards permit 
the amplification of endogenous controls and targets in cDNA samples using 
fluorogenic 5’ nuclease assays. The LDA card functions as an array of reaction 
vessels for the PCR/sequence detection step. It consists of 8 series of 48 intercalated 
wells. Each set provides a user-specified number of replicates. The wells contain 
dried Applied Biosystems TaqMan probes, labelled with the FAM dye, and primers 
for one mRNA target. Relative levels of gene expression were determined from the 
fluorescence data generated during the PCR using the ABI PRISM 7900HT Sequence 
Detection System and Comparative CT method using the Relative Quantification 
software. 
 
Figure 4.2: The Low Density Array Card. Adapted from (114). 
Protocol Low Density Array 
Do not remove the LDA card from its packaging before it has reached room 
temperature and you are ready to load it with sample-specific PCR reaction mix. 
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Prolonged exposure to indoor lightning can photo-degrade the fluorescent probes 
contained within the micro fluidic card. 
PREPARE THE SAMPLE-SPECIFIC PCR MIX: For each sample, add the following 
components to a labelled 1.5 ml microcentrifuge tube: 5 µl cDNA sample, 45 µl 
RNase/DNase-free water, 50 µl TaqMan Universal PCR master mix (2×). Cap the 
tube. Mix thoroughly by gentle vortexing and centrifuge briefly. 
LOAD FILL RESERVOIRS: Load 100 µl of the desired sample-specific PCR 
reaction mix, made from a single cDNA sample, into a 100 µl micropipette and 
dispense the entire volume in the fill port reservoir of the LDA card (foil side down). 
Insert the LDA card into a card holder and centrifuge the card to transfer the sample-
specific PCR reaction mix from the fill reservoirs to the reaction wells. Two 
consecutive 1 min centrifugations at 1200 rpm are needed to ensure complete 
distribution of the sample-specific PCR reaction mix and resuspend the dried Taqman 
probes and primers within the wells of LDA card. After centrifugation, examine each 
LDA card to determine whether the filling is complete. 
SEAL THE LDA CARDS: Use a LDA card sealer. Sealing should be done as soon as 
possible following centrifugation, reducing the risk of cross-contamination. If the 
sealing is successful, the LDA card is ready to be run on the 7900HT system.  
4.4 Serum analysis 
When handling serum samples; minimize freeze/thaw cycles, time that serum is 
thawed and sample temperature by keeping samples on ice or at 4ºC. 
4.4.1 Glucose Quantification 
The measurement of glucose in blood was performed immediately after blood was 
taken out by using an Accu-Chek Aviva. A droplet of blood was loaded on the front 
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yellow part of a test strip, already inserted into the Accu-Chek Aviva. The instrument 
automatically calculates the plasma glucose value.  
4.4.2 Insulin Quantification 
An ELISA (enzyme-linked immunosorbent assay) allows for rapid screening and 
quantification of the presence of an antigen in a sample. Mercodia Ultrasensitive 
Mouse Insulin ELISA kit (Cat.No: 10-1150-01) is a solid two-site immunoassay. It is 
based on the direct sandwich technique in which two monoclonal antibodies are 
targeted against different antigenic determinants on the insulin molecule. During 
incubation, insulin in the sample reacts with peroxidase-conjugated anti-insulin 
antibodies and anti-insulin antibodies bound to the microtitration well. A simple 
washing step removes unbound material in serum and unbound enzyme labelled 
antibody. The bound conjugate is detected by reaction with 3.3′ ,5.5′ 
tetramethylbenzidine (TMB). Adding acid stops the reaction and gives a colorimetric 
endpoint. The enzyme activity can be measured spectrophotometrically by the 
increased absorbance at 450 nm. The increase in absorbance is directly proportional 
to the amount of captured insulin in the unknown samples. The concentration of 
insulin can be calculated by interpolation from a calibration curve generated in the 
same assay with reference standards of known concentrations of mouse insulin.  
Protocol 
Store the kit components at 2 - 8°C. Each kit contains reagents for 96 wells, sufficient 
for 42 samples and one Calibrator curve in duplicate. Thaw serum samples on ice, 
vortex and centrifuge briefly. Put all kit reagents and samples to room temperature 
before use. Perform each determination in duplicates for calibrators and unknowns. 
Prepare a calibration curve for each assay run. Add 25 µl of calibrator 0 to each anti-
insulin well. Calibrators 3 to 7 and serum samples are performed in duplicates, 5 µl in 
each well. Add 50 µl enzyme conjugate to each well. Avoid contamination between 
the conjugate and substrate, by separating pipettes. Incubate on a plate shaker (700-
900 cpm, orbital movement) for 2 hours at room temperature. Aspirate the reaction 
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volume and wash six times with 350 µl Wash Buffer. After final wash, invert and tap 
the plate firmly against absorbent paper. Add 200 µl Substrate TMB. Cover the plate 
in aluminum foil and incubate for 30 min. Add 50 µl Stop Solution, shake the plate 
gently for 5 sec to ensure mixing of Substrate and Stop Solution. Measure the 
absorbance at 450 nm.  
Solutions 
Calibrators: Add 1 ml of redistilled water to each of the six calibrators. Calibrator 0 
is ready for use. 
Enzyme conjugate: Gently mix 600 µl of Enzyme Conjugate 11× with 6 ml of 
enzyme conjugate buffer. 
Substrate TMB: Ready for use. Light sensitive! 
Wash buffer: Dilute the wash buffer (40 ml) 21× in redistilled water (800 ml). 
Stop solution: Ready for use. 
4.4.3 Lipid Quantification 
Serum lipid quantification, using enzymatic in vitro tests, was performed by others on 
a Roche Hitachi 917. NEFAs were determined with a Wako NEFA C-kit (994-
75409), TAGs with a Roche Triglyceride GPO-PAP kit (11730711216) and 
cholesterol with a Roche Cholesterol CHOD-PAP kit (11491458216). 
4.5 Statistics 
All statistics were calculated using SPSS Software 14.0. The results are presented as 
mean of n values ± SEM. The level of statistical significance was set at P < 0.05. 
Significant differences were established by the Mann-Whitney test. General 
differences between groups (WT females, WT males, LXRα-/- females or LXRα-/- 
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males) were tested by pooling all data from 1-9 months within each group. All 
correlation analysis was compared by Spearman correlation coefficient.  
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5. Results 
5.1 Animal characteristics in female and male WT and 
LXRα-/- mice, aged 1-9 months 
C57BL/6 female and male mice (LXRα-/- and WT) were aged for 1, 3, 6 or 9 months. 
The bodyweight and organweight (liver and WAT) increase significantly from 1-9 
months in all mice (Table 5.1). 
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Table 5.1. Animal characteristics in ageing WT and LXRα-/- mice. (A) WT and 
(B) LXRα -/- male (M) and female (F) C57BL/6 mice, 1-9 months of age, were 
housed in a controlled environment and had ad libitum access to water and food 
(standard chow diet). N=4 in each group. Blood was taken from the heart and stored 
on ice until separation of serum. Serum analysis was performed as described in 
materials and methods. Values are means ± SEM. *p<0.05 vs 1 month values. 
Female mice, both LXRα-/- and WT, are significantly smaller than male mice, but no 
significant genotype-related differences are found ragarding bodyweight and 
organweight. In addition, 9 month old LXRα-/- and WT males weigh more or less 40 
gram, which is generally considered as obese.  
Furthermore, we measured glucose in blood (values are plasma calibrated) and 
different parameters in serum, including insulin and lipids (FFAs, cholesterol, TAG). 
The serum concentrations of TAGs, cholesterol, FFAs are not altered in an 
agedependent fashion in the mice studied (1-9 months) (Table 5.1). However, the 
levels of TAGs and cholesterol, but not FFAs are significantly lower in female mice 
of both genotypes. Albeit not significant (P = 0.056), LXRα-/- mice exhibit lower 
levels of cholesterol and TAG in serum compared to their WT littermates.  
The plasma glucose levels fluctuate within each group from 1-9 months, but are 
significantly higher in male mice of both genotypes compared to female animals. 
Insulin levels are also significantly higher in male mice compared to female mice, in 
both genotypes (Table 5.1 and Figure 5.1). In contrast to the glucose concentration, 
serum insulin levels are significantly age-induced in male WT mice (1- 9 months). 
The insulin levels are also significantly induced in male LXRα-/- mice, but this 
induction is only significant when comparing 1 to 3 months, and 1 to 6 months. In 
female LXRα-/- mice, there is a small, significant induction between 1 and 9 months, 
but this is not observed in female WT mice.  
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Figure 5.1. Insulin levels in serum of WT and LXRα-/- (KO) male (M) and female 
(F) C57BL/6 mice, 1-9 months of age. Animals were housed in a controlled 
environment and had ad libitum access to water and food (standard chow diet). N=4 
in each group. Blood was taken from the heart and stored on ice until separation of 
serum. Serum analysis was performed as described in the text. Values are means ± 
SEM. *p<0.05 vs 1 month values. 
Given that males weigh more than females, we thought it would be interesting to 
study the correlation between bodyweight and serum levels. Insulin levels correlate 
significantly with bodyweight and organweight (liver, WAT), whereas other 
measured serum components do not show similar correlation (1-9 months). 
Nevertheless serum TAG levels correlate significantly with serum levels of 
cholesterol and FFAs (1-9 months).  
5.2 Hepatic expression of selected genes in ageing mice 
(1-9 months) 
LXRs have profound effects in glucose, lipid and cholesterol metabolism. As LXRα 
is the dominant LXR isoform in liver (85), we investigate how LXRα influences the 
glucose and lipid metabolic pathways during ageing (1-9 months) in the liver of 
female and male LXRα-/- mice compared to WT littermates. This is done by 
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analyzing some basal mRNA expressions of genes involved in regulatory pathways, 
both ascending and descending, in glucose and lipid homeostasis. In addition, sex-
related changes are investigated, as discussed in section 5.2.5. 
The inhibitor of cyclin-dependent kinase 4 (INK-4) gene is a tumour suppressor gene. 
Given that the expression of INK-4 is known to increase during ageing in mammals 
(117), we seleceted INK-4 as a positive control for the ageing of mice in this study. 
With the exception of WT males, hepatic INK4 mRNAs increase significantly from 
1-9 months in the mice studied (Figure 5.2). 
 
Figure 5.2. Relative mRNA levels encoding INK4 in vivo. WT and LXRα-/- (KO) 
male (M) and female (F) C57BL/6 mice, 1-9 months of age, were housed in a 
controlled environment and had ad libitum access to water and food (standard chow 
diet). N=4 in each group. Mice were euthanized, livers were excised and total RNA 
was isolated using TRIzol® reagent. The expression was assessed by qRT-PCR and 
36B4 was used as an endogenous control to normalisation. Relative mRNA levels 
were related to 1 month old WT-M. Values are means ± SEM. #p<0.05 1 month vs 9 
month values. 
5.2.1 Genes involved in hepatic glucose metabolism 
Investigated genes at the mRNA level involved in glucose metabolism, include genes 
involved in glucose transport (GLUT2), glycolysis (GCK [phosphorlylates glucose to 
glucose 6-phosphate] and gluconeogenesis (PEPCK [decarboxylates oxaloacetate to 
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phosphoenolpyruvate], FBP-1 [dephosphorylates fructose 1,6-bisphosphate], G6P 
[hydrolyses glucose 6-phophate to free glucose]) (26). None of these genes have 
identified LXRE(s) in their promoter. 
Regarding glucose transport, it is known that GLUT4 is a direct target gene of LXRα 
in adipose tissue (100). However, the hepatic GLUT2 is not a known LXRα target 
gene. As such, we thought it would be interesting to investigate if LXRα regulates 
GLUT2 in liver. Indeed, the hepatic basal GLUT2 mRNA level is significantly lower 
in 1 month old female and male LXRα-/- mice compared to their WT littermates 
(Figure 5.3). Furthermore, GLUT2 mRNAs are significantly age-induced in LXRα-/- 
male mice from 1-9 months. In 9 month old LXRα-/- male mice the basal expression 
of GLUT2 is significantly higher compared to the mRNA levels in 9 month old WT 
males. A similar, albeit not significant pattern is observed in female LXRα-/- mice. 
 
Figure 5.3. Relative mRNA levels encoding GLUT2, involved in hepatic glucose 
transport in vivo. WT and LXRα-/- (KO) male (M) and female (F) C57BL/6 mice, 1-
9 months of age, were housed in a controlled environment and had ad libitum access 
to water and food (standard chow diet). N=4 in each group. Mice were euthanized, 
livers were excised and total RNA was isolated using TRIzol® reagent. The 
expression was assessed by qRT-PCR and 36B4 was used as an endogenous control 
to normalisation. Relative mRNA levels were related to 1 month old WT-M. Values 
are means ± SEM. *p<0.05 WT 1 month vs LXRα-/- 1 month values. #p<0.05 1 
month vs 9 month values. 
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The hepatic basal mRNA expression of GCK, involved in glycolysis, is only 
significantly higher in 1 month old female LXRα-/- mice compared to their WT 
controls. However, GCK is significantly age-induced at mRNA level from 1 to 9 
months in female and male LXRα-/- mice (Figure 5.4). A similar trend is observed in 
WT mice, but this is not significant.  
 
Figure 5.4. Relative mRNA levels encoding GCK, involved in glycolysis in vivo. 
WT and LXRα-/- (KO) male (M) and female (F) C57BL/6 mice, 1-9 months of age, 
were housed in a controlled environment and had ad libitum access to water and food 
(standard chow diet). N=4 in each group. Mice were euthanized, livers were excised 
and total RNA was isolated using TRIzol® reagent. The expression was assessed by 
qRT-PCR and 36B4 was used as an endogenous control to normalisation. Relative 
mRNA levels were related to 1 month old WT-M. Values are means ± SEM. *p<0.05 
WT 1 month vs LXRα-/- 1 month values. #p<0.05 1 month vs 9 month values. 
The basal mRNA expression of selected gluconeogenic genes (PEPCK, FBP-1 and 
G6P) are significantly downregulated in 1 month old male LXRα-/- mice compared to 
WT males (Figure 5.5). In 1 month old female LXRα-/- mice, this downregulation is 
only significant for the PEPCK gene. Furthermore, PEPCK mRNA levels increase 
significantly from 1-9 months in LXRα-/- male mice. A similar, but not significant 
trend is observed in LXRα-/- female mice. Interestingly, in WT mice the mRNA levels 
of the PEPCK gene seem to decrease from 1-9 months, however only significant in 
females. We also demonstrate a significantly higher expression of G6P mRNAs 
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between 1 and 9 months in LXRα-/- female mice. Nevertheless, G6P mRNA levels 
seem to fluctuate within this group and do not show a clear age-dependent trend. 
 
Figure 5.5. Relative mRNA levels encoding genes involved in gluconeogensis in 
vivo. WT and LXRα-/- (KO) male (M) and female (F) C57BL/6 mice, 1-9 months of 
age, were housed in a controlled environment and had ad libitum access to water and 
food (standard chow diet). N=4 in each group. Mice were euthanized, livers were 
excised and total RNA was isolated using TRIzol® reagent. The expression was 
assessed by qRT-PCR and 36B4 was used as an endogenous control to normalisation. 
Relative mRNA levels were related to 1 month old WT-M. Values are means ± SEM. 
*p<0.05 WT 1 month vs LXRα-/- 1 month values. #p<0.05 1 month vs 9 month 
values. 
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5.2.2 Genes involved in hepatic cholesterol metabolism 
Given the crucial role LXRα plays in modulating cholesterol metabolism, we 
investigated genes involved in hepatic cholesterol conversion into bile acids 
(CYP7A1), cholesterol efflux into bile (ABCG5, ABCG8), and cholesterol 
biosynthesis (3-Hydroxy-3-methylglutaryl Coenzyme A Synthase [HMGCS1]). 
In mice, CYP7A1 has an identified LXRE in its promoter and it is considered as a 
direct target gene of LXRα (118). Interestingly, a downregulation of CYP7A1 is only 
significant in 1 month old male LXRα-/- mice (Figure 5.6.A). Furthermore, in LXRα-/- 
mice there is an age-dependent induction (1-9 months) of CYP7A1 mRNAs in both 
females and males. However, in WT male mice, CYP7A1 mRNAs are significantly 
age-reduced from 1-9 months, whereas an opposite, but not significantly (P = 0.05) 
trend is observed in WT females. 
 
Figure 5.6. Relative mRNA levels encoding genes involved in cholesterol 
excretion (A) and biosynthesis (B) in vivo. WT and LXRα-/- male (M) and female 
(F) C57BL/6 mice, 1-9 months of age, were housed in a controlled environment and 
had ad libitum access to water and food (standard chow diet). N=4 in each group. 
Mice were euthanized, livers were excised and total RNA was isolated using TRIzol® 
reagent. The expression was assessed by qRT-PCR and 36B4 was used as an 
endogenous control to normalisation. Relative mRNA levels were related to 1 month 
old WT-M. Values are means ± SEM. *p<0.05 WT 1 month vs LXRα-/- 1 month 
values. #p<0.05 1 month vs 9 month values. 
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HMGCS1 is involved in cholesterol biosynthesis (26) and does not have any known 
LXRE in its promoter. Interestingly, the basal mRNA expression of HMGCS1 is 
regulated in mice studied. In 1 month old female and male LXRα-/- mice, the 
HMGCS1 mRNAs are significantly higher compared to WT controls (Figure 5.6.B). 
These levels remain higher in the LXRα-/- mice compared to WT mice in all ages (1-9 
months), suggesting that LXRα may have an inhibitory effect on the basal mRNA 
expression of this gene. Furthermore, HMGCS1 mRNAs are significantly age-
induced in WT females only. 
The ABC transporters, ABCG5/G8, are involved in hepatic cholesterol efflux into the 
bile (26). To this date, no LXRE(s) is identified in their promoters. We demonstrate 
that the basal mRNA levels of ABCG5/G8 are significantly downregulated in 1 
month old males compared to their WT littermates, but not in females (Figure 5.7).  
 
Figure 5.7. Relative mRNA levels encoding genes involved in cholesterol efflux 
into bile in vivo. WT and LXRα-/- male (M) and female (F) C57BL/6 mice, 1-9 
months of age, were housed in a controlled environment and had ad libitum access to 
water and food (standard chow diet). N=4 in each group. Mice were euthanized, 
livers were excised and total RNA was isolated using TRIzol® reagent. The 
expression was assessed by qRT-PCR and 36B4 was used as an endogenous control 
to normalisation. Relative mRNA levels were related to 1 month old WT-M. Values 
are means ± SEM. *p<0.05 WT 1 month vs LXRα-/- 1 month values.  
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5.2.3 Genes involved in hepatic lipid metabolism 
The role of LXRα in lipid metabolism is well characterized (30). Studies have shown 
that mice treated with LXR agonists exhibit increased hepatic lipogenesis, an effect 
that has largely been attributed to the LXR dependent upregulation of SREBP-1c 
expression (49;73;91). The SREBP-1c gene has two LXREs in its promoter (73;91), 
and can regulate expression of the de novo lipogenic genes FAS and SCD-1(91). 
However, treating SREBP-1c null mice with an LXR agonist, still results in the 
upregulation of lipogenic genes and an increase in FA synthesis, suggesting that 
additional mechanisms exist to link LXR activity and lipogenesis (119). Recently, it 
was demonstrated that ChREBP is a LXR target gene with two functional LXREs in 
its promoter, and that ChREBP also induces expression FAS and SCD-1 in agonist 
treated WT mice, but not in LXRα-/-β-/- mice (102). As both FAS and SCD-1 can be 
regulated by SREBP-1c, ChREBP and LXRα, we included SREBP-1 and ChREBP, 
as well as FAS and SCD-1 on the LDA card. We also included ELOVL1, ELOVL2, 
ELOVL5 and ELOVL6, genes involved in elongation of FAs in mammals (120) and 
acyl-CoA oxidase (ACO), which is involved in peroxisomal β-oxidation. 
The basal mRNA expression of SREBP-1 in 1 month old mice does not seem to be 
dependent on LXRα, as no downregulation is demonstrated in LXRα-/- males or 
females (Figure 5.8). In fact, a small, but significant upregulation of SREBP-1 
mRNA levels is observed in 1 month old LXRα-/- females when compared their WT 
littermates. Furthermore, a significant downregulation of ChREBP mRNAs is only 
observed in LXRα-/- males in comparison to WT males, but a similar trend is 
observed LXRα-/- females. A small, but significant age-induction is observed in 
LXRα-/- males (1-9 months). 
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Figure 5.8. Relative mRNA levels encoding TFs involved in lipid metabolism in 
vivo. WT and LXRα-/- male (M) and female (F) C57BL/6 mice, 1-9 months of age, 
were housed in a controlled environment and had ad libitum access to water and food 
(standard chow diet). N=4 in each group. Mice were euthanized, livers were excised 
and total RNA was isolated using TRIzol® reagent. The expression was assessed by 
qRT-PCR and 36B4 was used as an endogenous control to normalisation. Relative 
mRNA levels were related to 1 month old WT-M. Values are means ± SEM. *p<0.05 
WT 1 month vs LXRα-/- 1 month values. #p<0.05 1 month vs 9 month values. 
The selected genes involved in de novo lipogenesis, FAS (49;93) and SCD-1 (121), 
have an identified LXRE in their promoter. Our results demonstrate a significant 
downregulation of FAS and SCD-1 mRNAs in 1 month old female and male LXRα-/- 
mice compared to their WT littermates (Figure 5.9). Strikingly, the basal mRNA 
expressions of these genes are upregulated in LXRα-/- male and female mice from 1-9 
months. This age-induction is not significant for SCD-1 in LXRα-/- males (1-9 
months) although a similar trend is observed.  
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Figure 5.9. Relative mRNA levels encoding genes involved in de novo lipogenesis 
in vivo. WT and LXRα-/- male (M) and female (F) C57BL/6 mice, 1-9 months of age, 
were housed in a controlled environment and had ad libitum access to water and food 
(standard chow diet). N=4 in each group. Mice were euthanized, livers were excised 
and total RNA was isolated using TRIzol® reagent. The expression was assessed by 
qRT-PCR and 36B4 was used as an endogenous control to normalisation. Relative 
mRNA levels were related to 1 month old WT-M. Values are means ± SEM. *p<0.05 
WT 1 month vs LXRα-/- 1 month values. #p<0.05 1 month vs 9 month values. 
To this date, six enzymes, termed ELOVL 1-6, involved in elongation af FAs have 
been identified (120). They do not have any identified LXRE(s) in their promoter. 
We show that ELOVL6 mRNA levels are significantly downregulated in 1 month old 
LXRα-/- female and male mice when compared to WT controls and then significantly 
age-induced from 1-9 months (Figure 5.10), following the same pattern as FAS and 
SCD-1. The mRNA expression of ELOVL5, however is only significantly 
downregulated in 1 month old LXRα-/- male mice and is not age-induced from 1-9 
months. Furthermore, the mRNA expression levels of ELOVL1, ELOVL2 and ACO 
are not regulated by LXRα or in an age-dependent fashion (results not shown).  
 62 
 
Figure 5.10. Relative mRNA levels encoding genes involved in FA elongation in 
vivo. WT and LXRα-/- male (M) and female (F) C57BL/6 mice, 1-9 months of age, 
were housed in a controlled environment and had ad libitum access to water and food 
(standard chow diet). N=4 in each group. Mice were euthanized, livers were excised 
and total RNA was isolated using TRIzol® reagent. The expression was assessed by 
qRT-PCR and 36B4 was used as an endogenous control to normalisation. Relative 
mRNA levels were related to 1 month old WT-M. Values are means ± SEM. *p<0.05 
WT 1 month vs LXRα-/- 1 month values. #p<0.05 1 month vs 9 month values. 
5.2.4 Other metabolic genes 
Several genes encoding proteins involved in general metabolism were also included 
on the LDA card, such as circadian genes (Brain and Muscle Aryl Hydrocarbone 
ARNT-like Protein [BMAL1], Clock), NRs (ERα, ERRα, GR, Hepatocyte Nuclear 
Factor [HNF]-4α, LXRβ) and genes that are involved in different signaling cascades, 
such as insulin receptor substrate (Irs) 1, NFκB, sirtuin (Sirt) 1 and SREBP-1c 
modifiers (Insig1 and Insig2). They were included in order to look closer into 
potential compensatory mechanisms for the loss of the functional LXRα protein in 
knockout animals, and also to study their mRNA expression in ageing mice (1-9 
months).  
Since it is known that some NRs, such as ERα (122), ERRα (123) PPARα (124;125), 
REV-ERBs (126), interact with or regulate the basal expression of circadian genes, 
we investigated whether LXRα is involved in circadian gene regulation as well. 
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Strikingly, our data demonstrate that the basal mRNA expression of BMAL1 is 
significantly higher in 1 month old LXRα-/- mice compared to WT controls (Figure 
5.11). In addition, BMAL1 mRNA expression is significantly reduced in 3 months vs 
1 month old LXRα-/- mice. Furthermore, in female LXRα-/- mice, Clock mRNA levels 
are also significantly higher compared to WT females, although to a lesser extent than 
BMAL1.  
 
Figure 5.11. Relative mRNA levels encoding genes in circadian regulation. WT 
and LXRα-/- male (M) and female (F) C57BL/6 mice, 1-9 months of age, were housed 
in a controlled environment and had ad libitum access to water and food (standard 
chow diet). N=4 in each group. Mice were euthanized, livers were excised and total 
RNA was isolated using TRIzol® reagent. The expression was assessed by qRT-PCR 
and 36B4 was used as an endogenous control to normalisation. Relative mRNA 
levels were related to 1 month old WT-M. Values are means ± SEM. *p<0.05 WT 1 
month vs LXRα-/- 1 month values. #p<0.05 1 month vs 3 month values. 
The relative mRNA levels of investigated NRs, including LXRβ, ERRα HNF-4α and 
GR are not significantly altered in mice aged 1-9 months and do not seem dependent 
upon LXRα (results not shown). This is also the case for genes that are involved in 
different signaling cascades (Irs1, NFκB, Sirt1, Insig1 and Insig2) (results not 
shown).  
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5.2.5 Sex differences 
Our findings indicate that several metabolic genes are regulated differently at mRNA 
level by LXRα in liver in 1 month old male and female mice studied. This is 
demonstrated by the significant mRNA downregulation of CYP7A1 and ABCG5/G8 
in LXRα-/- males only, or by the significant higher mRNA expression of GCK in 
LXRα-/- females only. Furthermore, ERα was selected as a positive control for sexual 
dimorphism. The relative mRNA levels of ERα are significantly higher expressed in 
female livers compared to males in both genotypes (Figure 5.12). ERα is significantly 
age-induced (1-9 months) at mRNA level in the liver of LXRα-/- female mice only. 
 
Figure 5.12. Relative mRNA levels encoding ERα. WT and LXRα-/- male (M) and 
female (F) C57BL/6 mice, 1-9 months of age, were housed in a controlled 
environment and had ad libitum access to water and food (standard chow diet). N=4 
in each group. Mice were euthanized, livers were excised and total RNA was isolated 
using TRIzol® reagent. The expression was assessed by qRT-PCR and 36B4 was 
used as an endogenous control to normalisation. Relative mRNA levels were related 
to 1 month old WT-M. Values are means ± SEM. *p<0.05 female vs male (1-9 
months) values. #p<0.05 1 month vs 9 month values. 
In addition to ERα, several other genes are also differently expressed in liver of 
females and males when 1, 3, 6 and 9 month mRNAs for specific genes are pooled 
together within each group. Then, the mRNA levels of some NRs (GR, LXRβ) 
(results not shown), as well as mRNA levels of some genes involved in glucose 
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metabolism (FBP-1, GLUT2) and cholesterol/lipid metabolism (ABCG5/G8, 
CYP7A1, HMGCS1, ELOVL5, FAS) are also significantly higher expressed in the 
livers of female mice compared to male mice in both genotypes. Furthermore, in WT 
mice only, female animals had a significant higher mRNA expression of the 
ELOVL6 gene, and this difference was also observed in LXRα-/- mice, however not 
significant.  
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6. Discussion 
6.1 Use of animals as a model system 
Whereas the ageing process in invertebrates can be markedly altered by changing the 
expression of a single gene (i.e. insulin-like molecules (1)), the situation in mammals 
is far more complex in that a multiplicity of hormonal and other factors apparently act 
interdependently using various signaling modalities. Non animal models have limited 
power to study the involvement of NRs in the ageing process at the level of the 
organism. To investigate the interaction between diet, genetics and ageing in humans 
is difficult, because a controlled diet and environment of humans question ethical 
issues and is expensive, as well as complicated to perform. The versatility and power 
of the mouse model, makes it an invaluable tool to study metabolic factors in vivo, by 
making it possible to examine data of interest in a physiological context and compare 
results between different ages and genotypes. As such, mice were selected as a model 
and all data presented in this thesis are based on this model. C57BL/6 mice are 
frequently used in metabolic research, including research of the aging process. It 
should be emphasized that there is a genetic variation between mouse strains, such as 
in lipoprotein profiles (127) and susceptibility to diet-induced atherosclerosis (128-
131), with C57BL/6 as a potent model. 
To further reveal the physiologic and metabolic changes during senescence and 
ageing in vivo, LXRα-/- and WT mice were used. A possible limitation to this model 
is that alternative regulatory pathways, which is not or less important in a normal 
situation, might compensate for the loss of a functional LXRα. LXRα-/- mice were 
used, as LXRα is the dominant LXR isotype expressed in liver and is the major 
regulator of the hepatic glucose and lipid metabolism (25;111). LXRα-/- mice have 
deficiencies in hepatic LXR target gene expression that are not compensated for by 
the small levels of LXRβ present in this tissue (81;111;132). Furthermore, both male 
and female mice were used in this experiment in order to unravel sexual 
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dimorphisms. The use of male mice in research is often preferred to avoid the 
hormonal fluctuations present in female mice.  
The mice were fed ad libitum and had free access to water throughout the experiment. 
This model of ad libitum fed laboratory animals can be considered as a model for 
sedentary humans who are at risk of obesity and associated diseases. The C57BL/6 
mouse strain is normally lean when fed a normal chow diet. However, as ageing 
continued, the male mice developed obesity (9 months).  
The major part of the liver, approximately 80% by volume, is composed of 
hepatocytes. Other cell types include phagocytic Kuppfer cells, liver adipocytes, liver 
sinusoidal endothelial cells, small epithelial cells, erythrocytes and leukocytes (133). 
Thus, it should be emphasized that the described metabolic changes occur in the 
whole liver tissue, not only in the hepatocytes. In addition, only a small liver piece 
was used to isolate total RNA and later for profiling gene expression. It is possible 
that gene expression vary within the different parts of the liver. 
6.2 Methodology 
RNA analysis 
The use of TRIzol® reagent is widely used to isolate RNA from tissues and cells of 
human, animal and plant origin. It provides high yields and high quality RNA if done 
properly. Importantly, total RNA is isolated, not only the high molecular weight 
mRNA. However, the method has its limitations. Firstly, incomplete removal of 
phenols from RNA samples may cause a less efficient cDNA synthesis, as the 
enzyme Reverse Transcriptase is inhibited by phenols. Secondly, the presence of 
phenols in RNA samples may increase the risk of RNA degradation. To address this 
matter, the purity of all RNA samples was evaluated using the NanoDrop (described 
in 4.2.2). 
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Protein levels and mRNA expression 
The mRNA expression profile of tissues, do not necessarily correlate to the protein 
levels or enzyme activity, and may therefore be insufficient by themselves for the 
quantitative description of biological systems (134). This evidence include 
discoveries of posttranscriptional mechanisms controlling the protein translation rate, 
the half-lives of given proteins or mRNAs (135) and the intracellular location and 
molecular association of the protein products of expressed genes (136). There is a 
growing appreciation of the role of microRNA ([miRNA] small RNAs of ~22 
nucleotide bases) in post-translational regulation of protein expression. Without 
encoding any protein products themselves (137), they can inhibit target mRNA 
translation after the translation initiation step (138). In this way miRNAs can 
decrease translation of specific proteins, without affecting mRNA abundance. In view 
of these arguments, the mRNA data presented could serve as tool to further study 
proteome analysis, in which the protein complement expressed by a genome is 
investigated (139). This is a valuable analysis due to its potential to determine 
properties of biological systems that are not apparent by mRNA sequence analysis 
alone (134). Nevertheless, with the abovementioned taken into consideration, mRNA 
expression data are widely used as a tool to investigate gene expression.   
Probe for SREBP-1 
The probe used in qRT-PCR recognizes both subtypes of SREBP-1 (SREBP-1a and 
SREBP-1c). Thus, we are not able to distinguish their expression. Nevertheless, 
SREBP-1c is the dominant form in the adult liver and most other intact tissues, 
whereas SREBP-1a predominate in cultured cell lines (140), suggesting that we 
mainly investigated SREBP-1c expression levels. Along this line, it has been shown 
that the SREBP-1c:SREBP-1a ratios in mouse liver is 9:1. High ratios have also been 
found in human liver (141). 
 69
6.3 The role of LXR in ageing 
Some studies have shown that the expression of NRs varies between sexes and 
throughout lifespan in rodents (142-144). LXRα and LXRβ null animals are fertile, 
suggesting that these two NRs are not fundamental for embryonic development. This 
is not the case for their heterodimer partner RXRα, whose deletion leads to early 
death during mouse ontogenesis caused by placental abnormalities (145). The more 
severe developmental phenotype of RXRα-/- mice is explained by the fact that it alters 
signaling of several NRs. In situ hybridization studies on mouse embryos have 
revealed the onset and pattern of expression of LXRs during embryogenic 
development. The mRNAs for both LXR isoforms are initially detected in liver 11.5 
days postcoitum (d.p.c.) (144). Later in development, expression pattern of LXRs 
differs. At 16.5 d.p.c. LXRα is expressed in several metabolic tissues, such as in 
brown adipose tissue and the small intestine, whereas the expression of LXRβ is 
more ubiquitous, with a particular enrichment in endocrine, immunological and 
neuronal structures. In adult mice, the LXRs are expressed as described previously 
(see 1.2.1.). Furthermore, a study performed on 3 month old and 18 month old female 
and male Sprague-Dawly rats by Sanguino et al. (142), demonstrated that the hepatic 
content of LXRα protein was higher in old male rats compared to their younger 
littermates, but their specific binding to a LXRE oligonucleotide 
(5’GCTTTGGTCACTCAAGTTCAAGTTA-3’) was reduced by 60% in comparison 
with samples obtained from young males. The binding to LXRE was investigated by 
using electrophoretic mobility shift assay (EMSA). On the contrary, there was no 
change in hepatic LXRα protein level and binding activity in female rats. 
It is known that dysregulated glucose and lipid metabolism, two metabolic pathways 
where LXRs play a critical role, increase the risk for several age-associated diseases 
(i.e. insulin resistance and T2DM, atherosclerosis, hyperlipidemia and obesity, all of 
which might precipitate into cardiovascular and neuropsychiatric diseases). 
Therefore, it is not surprising that deregulated transcription and activity of LXRs 
have been observed in several pathophysiological conditions which are also described 
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as age-related diseases, such as CVD and T2DM (146). Along this line, numerical 
animal studies have suggested LXRs as potential pharmaceutical targets to attenuate 
the development of hypercholesterolemia (i.e. atherosclerosis (77)) and T2DM 
(75;99). The anti-atherogenic effects may be subscribed to LXRs regulating genes 
involved in the cholesterol efflux (ABCA1, ABCG1, apoE), cholesterol conversion to 
bile acids (CYP7A1) and cholesterol secretion into bile for excretion (ABCG5/G8) 
(147). Indeed, administration of potent, selective LXR agonists may reduce aortic 
lesion formation (148), and even lesion regression (149) in atherogenic mouse strains. 
The anti-diabetic effects of LXRs have been investigated in several studies where 
synthetic LXR agonists decrease glucose levels (99) and improve insulin sensitivity 
by downregulating hepatic gluconeogenic genes, such as PEPCK and glucose 6-
phosphate dehydrogenase, and promoting glucose uptake through GLUT4 in adipose 
tissue (75;99). Interestingly, it has been demonstrated that a functional GLUT4 
protein is crucial for sustained growth, normal cellular glucose and lipid metabolism 
and longevity. GLUT4 knockout mice are growth retarded and exhibit a decreased 
longevity associated with cardiac hypertrophy and severly reduced adipose tissue 
deposits (150). In view of these findings, negative side effects of LXR agonist 
administration, such as hepatic steatosis and hypertriglyseridemia are observed in 
some animal studies (49;151), partly due to elevated hepatic fatty acid synthesis and 
VLDL secretion. The cellular benefit to increasing lipogenesis in the presence of 
excess free cholesterol, is not clear to this date, however, some theories have been 
purposed. Firstly, it may improve the ratio of cholesterol to other lipids in order to 
maintain plasma membrane fluidity (91). Secondly, most mammals do not ingest pure 
cholesterol, but rather diets containing both fat and cholesterol. The ability to store 
these excess calories as lipids could be beneficial (152). Either way, this enhanced 
lipogenesis has temporarily hampered the development of LXR agonists in the 
treatment of atherosclerosis and T2DM. To further investigate the impact of LXRs in 
the ageing process, we studied the role of LXRα in a normal physiologic context. 
Untreated LXRα-/- mice and their WT littermates (females and males, aged 1-9 
months), were included.  
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Our data demonstrate no genotype-related difference in bodyweight from 1-9 months, 
but in general, females are significantly smaller than males. Bodyweight in mice 
studied increased significantly during ageing (1-9 months). This pattern is similar to 
the change of organweight (liver and WAT). Total body fat was not measured, but 
the reproductive fat pad may serve as an indicator for total body fat changes. Mice 
further aged up to 20 months, lost bodyweight after the age of 13 months (results not 
shown). This effect might be due to loss of appetite, hormonal changes (i.e. decline in 
testosterone levels with age etc.), depression, organ atrophy or other factors.  
Plasma glucose levels fluctuate within each genotype group in ageing mice (1-9 
months), but were significantly higher in male compared to female mice. These 
findings were also observed in older mice aged 9-20 months (not shown). Even 
though plasma glucose levels remain unchanged in mice studied, it should be 
mentioned that plasma glucose is considered as a promising agent for involvement in 
the mechanisms of ageing. This arises from the fact that glucose, in addition to being 
an essential tissue nutrient, may accelerate degenerative processes. Elevated plasma 
glucose levels have deleterious consequences, including impaired glucose tolerance, 
insulin resistance and increased risk of age-related diseases, such as T2DM (153). 
Furthermore, elevated levels of plasma glucose may cause accumulation of advanced 
glycation end products (AGE), which modifies the structure of macromolecules, such 
as proteins and DNA. These findings led Cerami et al. to propose the Glycation 
Hypothesis of Ageing (154). Consistent with this theory, there is now stronger 
evidence for the inverse relationship between AGE formation rates and species-
specific lifespan. AGEs do accumulate on long-lived human proteins as a function of 
age (155), and to a bigger extent in diabetic individuals (156). There is also evidence 
that formation of AGE promotes oxidative stress and, conversely, that oxidative 
stress may lead to formation of AGE. Such positive feedback loops, would promote 
the accelerated tissue degeneration typical of ageing (157). Although numerous 
studies have deciphered how glucose and other nutrients can directly lead to a 
metabolic response, such as insulin secretion or lipogenic gene expression (158), little 
is known of how this is accomplished mechanistically. Glucose may be an 
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endogenous ligand of LXR with the same efficacy to that of oxysterols, as recently 
suggested by Mitro et al. (67), but this has not been proven in a physiological setting. 
Thus, it is tempting to question whether glucose acts through alternative pathways to 
modify LXR activity. Along this line, no crystal structural studies have identified a 
binding of glucose to LXR. Nevertheless, it is possible that glucose modifies LXR 
activity in vivo by other mechanisms, such as changing subcellular localization of 
LXRs, post-translational modification (i.e. phosphorylation) or by fascilitating 
recruitment of coactivators that interact with LXR. In view of these theories, it is 
demonstrated that glucose affects subcellular translocation of LXRα in pancreatic β-
cells without affecting the LXRα protein level (159). The molecular basis of how 
glucose affects LXR, remains to be elucidated, but could provide further evidence to 
how LXRs integrate hepatic glucose and lipid metabolism. 
Insulin has been identified as another pro-ageing factor (2;3). In the worm 
Caenorhabditis elegans, the insulin signaling pathway determines the response to 
longevity and environmental stress (160). Results from this thesis, demonstrate that 
the serum insulin concentration is significantly higher in male mice of both genotypes 
when compared to their female littermates (1-9 months). Given that male mice of 
both genotypes weigh more than their female littermates, it is possible that this 
difference in serum insulin is caused by the difference body- and organweight (liver, 
WAT). Along this line, we found a positive correlation between insulin and and 
body- and organ weight supporting this theory. Furthermore, the serum insulin levels 
in male LXRα-/- mice increase significantly from 1-3 months, an effect that is also 
significant from 1-6 months, but not from 1-9 months. It is therefore possible that 
LXRα crosstalks with insulin signaling early in life, but this needs to be rigoursly 
tested before any conclusion can be made, especially since insulin concentrations in 
serum do not follow the same pattern in LXRα-/- females, where a small increase in 
insulin levels is only significant from 1-9 months. Nevertheless, the link between 
LXRs and insulin signaling is supported by the fact that LXRs, in particular LXRβ, 
seem to be important for pancreatic insulin secretion, and that LXR activators 
promote insulin secretion (161;162). This highlights the potential of LXR agonists as 
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insulin sensitizers, as investigated in several models (99;163-165). Furthermore, a 
study on C57BL/6 WT female mice given a normal diet showed that insulin levels 
were induced from 2-12 months (166). In contrast to this finding, insulin levels do 
not increase significantly in WT female mice (1-9 months) studied in this thesis. 
However, we demonstrate a significant induction in serum insulin levels in ad libitum 
fed WT male mice aged 1-9 months. The increase in serum insulin levels in WT 
males (1-9 months), combined with their unchanged plasma glucose levels may 
indicate an early stage of insulin resistance as more insulin is needed to keep the 
glucose levels within a narrow range. This is consistent with reports of increased 
serum insulin levels (167), impaired glucose tolerance and decreased insulin 
sensitivity associated with ageing (168;169), which could exacerbate the imbalance 
between death and survival signals and contribute to increased cell loss and apoptosis 
associated with ageing and senescence (170). Furthermore, long lived mouse mutants 
exhibit reduced circulating levels of glucose and insulin (171-173). C57BL/6J mice 
are believed to carry a genetic predisposition to develop T2DM. Challenging 
C57BL/6J mice with a high-fat diet, has previously shown to induce insulin 
resistance (174). Obesity can cause insulin resistance, higher circulating insulin 
levels, and increased incidence of diseases that might have as their basis uncontrolled 
insulin signaling (175;176). For example, insulin resistance is a major pathogenic 
factor in the development of T2DM. Along this line, there is evidence that long-lived 
humans have decreased insulin signaling (177). Furthermore, one of the physiological 
characteristics in centenarians is their greatly increased insulin sensitivity compared 
with younger subjects (178;179). We have previously investigated the link between 
insulin and LXR in regulating hepatic FA synthesis and glucose metabolism (96). 
Insulin induces the LXRα mRNA levels in liver, leading to an increase in steady state 
mRNA level of LXR target genes, such as SREBP-1c as several genes encoding 
enzymes in FA and cholesterol biosynthesis. In addition, LXRα-/-β-/- mice exihibit 
suppressed insulin-mediated induction of an entire class of lipogenic and 
cholestrogenic enzymes, supporting the role of LXR as insulin sensors in hepatic 
lipid homeostasis (96). 
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From this study, the levels of lipids in serum (TAG, cholesterol, FFAs) are not altered 
in an age-related fashion (1-9 months). There is a small, albeit not significant increase 
in serum TAGs of 9 months old WT males compared to 1 month old WT males. 
Assessing the serum lipid profile in older animals (up to 20 months), will be useful in 
order to investigate if serum lipids increase during ageing. Nevertheless, one can not 
rule out that serum lipids do not change with age, as observed in a study on aged 
male Brown-Norway rats (5 months vs 24 months) (167). Our results demonstrate 
that senescent mice present a gender-related lipid-metabolic phenotype. The levels of 
TAGs and cholesterol, but not FFAs are significantly lower in females compared to 
males in both genotypes. This sex-difference in serum lipid levels may partly be 
related to the higher mRNA expression of ERα (Figure 5.12) or GR (results not 
shown) in females, altered hepatic expression or activity of other NRs than 
investigated in this thesis, as well as the presence of higher estrogen levels in females 
(not measured). This is further discussed in “sex differences” below. Regarding 
genotype differences in serum lipids, we observed that LXRα-/- mice (females and 
males) exhibit lower levels of TAGs and cholesterol in serum compared their WT 
littermates, but this difference is not significant. Nevertheless, it is possible that these 
lipids are stored in the liver in the LXRα-/- mice, as discussed below in “LXRα 
regulated genes during ageing (1-9 months).”  
The fact that mice were not fasted overnight before they were euthanized, one might 
argue that lipid values are affected by over-night dietary consumption. However, one 
of the aims in this study was that the mice would live as “natural” as possible with 
free access to food and water at all times. Fasting could interrupt the environment that 
the mice are used to, especially in old mice, and introduce a stress reaction with 
unwanted consequences. Allthough the serum values could differ if we had fasted the 
mice over night before sacrifice, it is likely that the trends with increased lifespan are 
the same in non fasted vs over night fasted mice.  
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Hepatic mRNA expression of selected genes 
The tumour suppressor gene, INK4, was selected as a positive control for ageing, as 
the expression of this gene is known to increase throughout lifespan in mammals 
(117). This is consistent with the results presented (Figure 5.2). It has been proposed 
that this upregulation of INK4 is directly involved in a decreased self-renewal 
potential of some mature stem cells (180). 
LXRα regulated genes during ageing (1-9 months) 
Several metabolic genes were regulated at mRNA level by LXRα. Genes involved in 
glucose metabolism (GCK, GLUT2, G6P, FBP-1, PEPCK) were all regulated by the 
LXRα in either females or males (See 5.2.1). Along this line, the role of LXRs in 
regulating glucose homeostasis, has been previously evaluated (75). The dual 
LXRα/β agonist, GW3965, enhanced glucose tolerance in a mouse model of diet 
induced insulin resistance. In liver of LXR ligand treated mice, the expression of 
gluconeogenic enzymes, such as PEPCK and G6P, was indirectly suppressed. The 
alterations in PEPCK mRNAs that we demonstrated (Figure 5.2) do probably not 
change the gluconeogenic flux by itself, as it has been pointed out that only severe 
reductions (-90%) or drasic increases (+300%) of PEPCK expression are associated 
with changes in gluconeogenesis in mice (181). Our group has previously shown that 
the insulin sensitive glucose transporter, GLUT4, is directly regulated by LXR in 
adipose tissue (100), further underlying the role of LXR in glucose metabolism. 
GLUT4 is capable of transporting glucose, a substrate for de novo lipogenesis, into 
adipocytes. This transport is probably important in a fasting refeeding situation. 
Interestingly, our data indicate that the basal expression of a hepatic glucose 
transporter, GLUT2, is dependent upon LXRα in a normal physiological situation 
(Figure 5.3). This link has not previously been described. 
LXRs are also important in regulating cholesterol and FA metabolism in multiple 
tissues, including the liver and intestine, as well as in macrophages. CYP7A1 is the 
rate limiting enzyme in converting excess cholesterol into bile acids. The expression 
of this CYP7A1 is described to be dependent on LXRα, but not LXRβ (81). This 
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LXRα-specific response may be due to the greater abundance of LXRα than LXRβ in 
the liver (85), or alternatively LXRα may have a higher activity than LXRβ in 
activating this specific gene. We show that the basal mRNA levels of this gene were 
significantly reduced in livers of LXRα-/- 1 month old males, indicating reduced 
cholesterol excretion (Figure 5.6.A). However, a significant upregulation of CYP7A1 
is observed in LXRα-/- mice (1-9 months, both females and males), indicating that 
other proteins compensate for the functional loss of LXRα in regulating CYP7A1 to 
promote cholesterol elimination. Furthermore, there was a decrease in CYP7A1 
mRNAs in 9 month old WT males. This may reflect the weakened binding of LXRα 
to LXRE in the liver of old male rats (18 months) compared to younger littermates (3 
months), shown by others (142). They also demonstrated that that the LXRα protein 
and its binding capacity to an LXRE, were not changed in old compared to young 
female rats, supporting our finding that CYP7A1 mRNA expression does not 
decrease in WT females. HMGCS1 is important for cholesterol biosynthesis. This 
gene was significantly higher expressed at mRNA level in 1 month old LXRα-/- mice 
of both sexes compared to their WT littermates (Figure 5.6.B). The mRNA levels also 
remained higher in female and male LXRα-/- mice from 3-9 months compared to WT 
controls. Mangelsdorf et al. has previously demonstrated that HMGCS1 mRNA 
levels were down regulated in response to a 2% cholesterol diet in both WT and 
LXRα-/- mice (81). As the regulation occurrs both in mice with and devoid of LXRα, 
this suggests that the down regulating effect may be due to cholesterol, and not the 
LXRα per se. Along this line, the rate limiting enzyme in cholesterol biosynthesis, 
denoted HMG CoA reductase, is known to be inhibited by cholesterol (182). Our 
finding in LXRα-/- mice fed a standard chow diet indicates that LXRα may be 
important in suppressing the expression of this HMGCS1. This underlines the 
dysregulated cholesterol metabolism in LXRα-/- mice, as increased cholesterol 
synthesis (HMGCS1) seems to happen simultaneously with decreased conversion of 
cholesterol to bile acids (CYP7A1). Together with our data demonstrating lower 
serum cholesterol in LXRα-/- mice, this suggests that excess cholesterol is stored in 
hepatic tissue of these animals. Other genes involved in cholesterol metabolism, 
include the ABCG5 and ABCG8, genes important for hepatic cholesterol efflux into 
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bile. They are target genes of LXRs and expressed in liver and intestine (83). 
Strikingly, the basal mRNA expression of these genes was only lower in LXRα-/- 1 
month males compared to LXRα-/- females (Figure 5.7). 
FAS and SCD-1 are direct LXR target genes involved in de novo lipogenesis. 
Whereas FAS is involved in FA biosynthesis, SCD-1 is the rate limiting enzyme 
necessary for the conversion saturated FAs into monounsaturated FAs (MUFAs). 
Vessby et al. has previously shown that an increase in dietary MUFAs resulted in 
improved insulin sensitivity in healthy men and women (183), but had no effect on 
insulin secretion. Therefore, hepatic steatosis in which TAGs contain relatively more 
MUFAs, might be “healthier” than steatosis with predominantly saturated FAs 
containing TAGs. Moreover, we demonstrate a lower mRNA basal expression of 
FAS and SCD-1 in LXRα-/- mice (Figure 5.9), suggesting that LXRα is important for 
their expression early in life. Strikingly, a gradual increase in their mRNA levels is 
observed in older mice (3-9 months), illustrating that other proteins may come into 
play. This trend was also demonstrated by the mRNA regulation of ELOVL6 (Figure 
5.10), an enzyme involved in elongation of saturated FAs or MUFAs, either ingested 
from the diet or synthesized in de novo lipogenesis (120). LXRβ is thought to 
compensate for the loss of LXRα in adipose tissue (184), but proof of this 
overlapping function in liver is lacking. Furthermore, the mRNA levels of LXRβ did 
not change in ageing mice (1-9 months, results not shown), suggesting that other 
proteins are responsible for the compensatory mechanism. LXR-mediated hepatic 
lipogenesis has been largely attributed to its ability to increase the expression and 
activity of the insulin-sensitive SREBP-1c gene. As both SCD-1 and FAS are under 
transcriptional control of both SREBP1-c (185) and LXR, one might speculate 
whether this is the responsible protein. However, the SREBP-1c mRNAs did not 
change significantly in neither genotype or between sexes in mice studied. Another 
potential candidate responsible for this effect, could be the glucose-sensitive 
transcription factor ChREBP, which is a LXR target gene (102). LXR and RXR 
agonists specifically induce ChREBP expression in WT mice, but not in LXRα-/-β-/- 
mice, a regulation dependent on two LXREs in the promoter of the ChREBP gene 
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(102). Furthermore, the ChREBP mRNA expression was almost abolished in fasted 
refed STZ treated LXRα-/-β-/- mice (Holm et al., unpublished results), indicating that 
the expression of ChREBP is dependent on LXRs. As such, LXRβ may activate 
ChREBP which then promotes the induction of lipogenic genes. Furthermore, both 
SREBP1-c and ChREBP are regulated to a large degree by post-translational 
mechanisms (102), not investigated in this study. SREBP-1c is tethered in the 
endoplasmatic reticulum, as well as the nuclear envelope membranes. Under low-
cholesterol conditions it is released and translocated to the Golgi via SREBP 
cleavage-activating protein escort, followed by proteolytic cleavage by site 1 protease 
and site 2 protease to release the TF component of this protein (140). ChREBP is 
located in the cytosol by PKA-mediated phosphorylation of residues, which promotes 
the interaction with the protein 14-3-3 (186). High intracellular glucose levels 
increase the formation of xylulose 5-phosphate to increase the activity of protein 
phosphatase 2A to promote ChREBP nuclear localization (187). 
Circadian rhytms are an important aspect of human biology. Many physiological 
processes display day-night rhythms, such as feeding behaviour, lipid and 
carbohydrate metabolism, blood pressure control and sleep-wake cycles (188). In 
addition circadian rhytmicity is revealead for every hormone in the circulation (189). 
The mammalian circadian system is organized in a hierarchy of oscillators. At the top 
of this hierarchy is the suprachaismatic nucleus (SCN) of the anterior hypothalamus. 
This “master” oscillator contols the circadian rhytm. However, endogenous 
oscillators have also been identified in peripheral organs, such as liver, heart and 
kidney (190). Circadian genes, such as Period1 (Per1), Per 2, BMAL1, Clock and 
REV-ERBα are expressed not only in the SCN, but also in peripheral tissues (191). 
These genes are involved in regulating the circadian rhythm. BMAL1 dimerises with 
Clock and transactivates expression of genes involved in circadian regulation by 
binding to E-box elements in their promoters. In addition, it is known that the input 
and output pathways of the hypothalamic suprachiasmatic nuclei (SCN), as well as 
the function of this central pacemaker itself, change with advanced age (189). 
Interestingly, our data demonstrate a link between LXRα and circadian regulation, 
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which has not been described previously. The basal mRNA level of the circadian 
BMAL1 gene is significantly upregulated in both male and female 1 month old 
LXRα-/- mice but then significantly downregulated in 3 months compared to 1 month 
old LXRα-/- mice. We also observed an upregulation of Clock mRNA levels in 1 
month old female LXRα-/- mice. However, this effect is less pronounced than the 
upregulation of BMAL1. This suggests that LXRα may be involved in suppressing 
the expression of circadian genes early in life (1 month). Whether this is the case for 
other circadian genes, would be interesting to investigate further, but is not within the 
scope of this thesis. In view of our finding, collaborators in the CRESCENDO project 
further investigated the link between LXRα and other circadian genes. Strikingly, 
they found that the mRNA expression levels of several other circadian genes were 
affected in the 1 month old LXRα-/- mice used in this thesis (preliminary results, 
Delaunay et al.). Nevertheless, these observations need to be further examined, but 
are potentially very interesting, as LXRα may influence the circadian regulation in 
mammals.  
Taken together, these results underline the role of LXRα in glucose, cholesterol and 
lipid metabolism and that the regulation is differently regulated in some genes with 
increased life span. Strikingly, this includes regulation of genes that do not (yet) have 
identified LXRE(s) in their promoter, such as the case for ELOVL-6. Furthermore, 
the potential crosstalk with LXR and circadian genes may be the beginning of an 
emerging field. 
Sex differences  
When specific mRNAs for target genes of LXRα were evaluated, numerous 
differences between males and females were observed. Our findings indicate that 
several metabolic genes are regulated differently by LXRα in liver in 1 month old 
male and female mice studied. This is demonstrated by the significant mRNA 
downregulation of CYP7A1 and ABCG5/G8 in LXRα-/- males only, or by the 
significant higher mRNA expression of GCK in LXRα-/- females only. Furthermore, 
when 1, 3, 6 and 9 month mRNAs for specific genes were pooled together within 
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each group, females exhibited significantly higher hepatic relative mRNA levels of 
genes involved in glucose metabolism (FBP-1, GLUT2), as well as genes involved in 
cholesterol (ABCG/G8, HMGCS1, CYP7A1) and lipid metabolism, (ELOVL5/6, 
FAS). As both TAGs and cholesterol serum levels were lower in females, it is 
tempting to hypothesize that cholesterol and lipid metabolism is differently regulated 
under the control of LXRα between sexes, such as a higher cholesterol turnover and 
higher de novo lipogenesis in female animals. These findings have to be investigated 
further, for instance by analyzing lipids (TAGs and cholesteryl esters) in liver tissue. 
Along this line, the sexual dimorphism in mRNAs of genes encoding proteins 
involved in hepatic metabolic pathways may be subscribed to several factors. Firstly, 
as already mentioned, it is possible that LXRα regulates genes differently in females 
and males. Data supporting this theory is scarce and need to be clearified. 
Nevertheless, in an age-dependent manner, as shown in a study by Sanguino et al., 
both hepatic LXRα protein expression and activity was altered in senescent male rats, 
but not in female rats (142). Secondly, there might be a crosstalk with LXRs and ERs 
in females, but this is not well established. Thirdly, some sexual dimorphic features 
may be subscribed to hormonal differences. It is widely accepted that estrogen and 
testosterone levels differ in female and male mice, although not measured. Given the 
well known reduction in testosterone levels with age, it is possible that this may 
explain some sexual differences observed in senescent animals, as well as differences 
between young and old males. Fourthly, age- and sex dependent hepatic expression 
of other NRs may influence mRNA levels in an LXRα independent manner. From 
our experiments, mRNAs of ERα and GR were higher expressed in female livers. 
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7. Conclusion 
The major activities of LXR in modulating the expression of genes involved in the 
glucose and lipid metabolic pathway enables the organism to adapt their fluctuating 
nutritional status and environmental conditions (i.e. food deprivation) by sensing the 
body’s energy reservoir. Since the LXRα regulate multiple aspects of glucose and 
lipid metabolism, it is not surprising that deregulated transcription and activity of 
LXRα have been observed in several pathophysiological, age-related conditions, such 
as CVD and T2DM. Our data indicate that LXRα is important in regulating lipid and 
glucose metabolism during ageing in a normal physiological setting. Several hepatic 
LXRα target genes seem to be regulated during the ageing process, such as the de 
novo lipogenic genes FAS and SCD-1. Their basal mRNA expression is dependent 
upon LXRα in 1 month old animals. A gradual increase in the expression of these 
genes, occur in LXRα-/- female and male mice (1-9 months), indicating that other 
mechanisms/proteins come into play to compensate for the loss of LXRα. A similar 
trend is observed in the regulation of ELOVL6, a gene involved in elongation of FAs, 
which is not described as an LXRα target gene. In addition, several other genes seem 
to be regulated by LXRα, including CYP7A1, HMGCS1, PEPCK, and GLUT2. With 
the exception of GLUT2, these genes do not show any compensatory effect at mRNA 
level as for the genes mentioned above. Furthermore, this is the first report assessing 
the link between LXRα and circadian regulation. Our data show that LXRα is 
important in regulating the basal mRNA expression of the circadian gene, BMAL1, 
in 1 month old animals. As such, it is tempting to speculate that LXRα is involved in 
circadian regulation early in life. How this could affect ageing is potentially very 
interesting. Furthermore, it is known that the input and output pathways of the SCN, 
as well as the function of this central pacemaker itself, change with advanced age. 
However, the role of LXRα in circadian regulation remains to be investigated. 
Interestingly, this study also reveals many differences between female and male mice, 
regarding plasma glucose and measured serum components (i.e. insulin, TAG, 
cholesterol), as well as relative mRNA expression levels of specific genes (i.e. 
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ABCG5/G8, CYP7A1, FBP-1, GLUT2). In view of these data, it is still difficult 
making major concluding remarks of the role of LXRα in the ageing process, as the 
serum values and the gene expression pattern may change in mice older than 9 
months. By studying changes in mice aged from 9 to 20 months and by including 
LXRβ-/- mice, as well as other tissues/organs, a more complete picture of the link 
between LXRs and ageing may be provided. Although beyond the scope of this 
study, the suspected importance of LXRs in mammalian and especially human 
longevity and age-dependent diseases through control of lipid and glucose 
metabolism remains to be rigorously tested. In order to further evaluate this topic, the 
potential crosstalk with other tissues/organs, NRs, hormones and cofactors must be 
addressed, as no single pathway is believed to function in an isolated manner. In fact, 
it is more likely that the combined forces of multiple genes embedded in many 
networks act together. Furthermore, it remains to be elucidated if similar differences 
are present in humans.  
7.1 Future perspectives 
• Continue ageing by including mice of 13, 16 and 20 months  
• Assess lipid profile (TAGs and cholesteryl esters) in liver tissue 
• Perform hyperinsulinemic euglycemic clamp in young and very old mice to 
describe physiological changes in insulin mediated glucose and lipid 
metabolism. 
• Include LXRβ-/- mice to evaluate its function in ageing.  
• Include LXRα-/-β-/- mice up to 3 months to obtain information of compensatory 
mechanisms that might come to play for loss of these receptors in the early 
stage of life.  
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• Study genes of interest in other tissues excised (heart, pancreas, WAT 
(epididymal and subcutaneous), musculus soleus and musculus 
gastrocnemius). 
• In order to further validate the findings, it would be interesting to examine 
food consumption and other whole-animal measurements, such as total daily 
physiological activity, body temperature, metabolic rate and ageing pathology 
(i.e. glucose sensitivity, T2DM).  
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